Valparaiso University

ValpoScholar
Evidence-Based Practice Project Reports

College of Nursing and Health Professions

5-12-2014

Effects of an APN-Led Amiodarone Clinic on
Adherence to Recommended Monitoring
Guidelines
Melissa Bartoszewicz
Valparaiso University

Follow this and additional works at: http://scholar.valpo.edu/ebpr

Recommended Citation
Bartoszewicz, Melissa, "Effects of an APN-Led Amiodarone Clinic on Adherence to Recommended Monitoring Guidelines" (2014).
Evidence-Based Practice Project Reports. Paper 57.

This Evidence-Based Project Report is brought to you for free and open access by the College of Nursing and Health Professions at ValpoScholar. It has
been accepted for inclusion in Evidence-Based Practice Project Reports by an authorized administrator of ValpoScholar. For more information, please
contact a ValpoScholar staff member at scholar@valpo.edu.

VALPO
EFFECTS OF AN APN-LED AMIODARONE CLINIC ON ADHERENCE TO
RECOMMENDED

MONITORING GUIDELINES
by

MELISSA BARTOSZEWICZ
EVIDENCE-BASED

PRACTICE PROJECT REPORT

Submitted to the College of Nursing
of Valparaiso University,
Valparaiso, Indiana
in partial fulfillment of the requirements
For the degree of
DOCTOR OF NURSING PRACTICE

2014

~k:¥=

Advisor

~r./)./s?
Date

© COPYRIGHT
MELISSA BARTOSZEWICZ
2014
ALL RIGHTS RESERVED

ii

DEDICATION
I would like to dedicate this evidence-based project report to my husband, Ed, and
children, Joe and Liz, for supporting me throughout this three-year journey. Without their love
and support, I would never have made it to the finish line.

iii

ACKNOWLEDGMENTS
I would like to extend my gratitude to my advisor, Dr. Theresa Kessler, for her words of
encouragement and most of all for her creation of deadlines throughout this project adventure.
Without her critiques and keeping me on track, I would have never finished this project. I would
also like to thank my clinical advisor, Dr. Naseer Nasser, for his support of my advancement in
my nursing career and in the creation of the amiodarone clinic. Finally, my thanks go out to Barb
Stitt, for being my cheerleader throughout this three-year process and always reminding me to
take things one day at a time.

iv

TABLE OF CONTENTS
Chapter

Page

DEDICATION……………………………………………………………………………………iii
ACKNOWLEDGMENTS……………………………………………………………..………...iv
TABLE OF CONTENTS……….………………………………………………………….…….v
LIST OF TABLES……….……………………………………………………………………...vi
LIST OF FIGURES..……....…………………………………………………………..….…...vii
ABSTRACT……….……………………………………………………………….………..….viii
CHAPTERS
CHAPTER 1 – Introduction...........…………………………………………………....1
CHAPTER 2 – Theoretical Framework and Review of Literature…………..…...13
CHAPTER 3 – Implementation of Practice Change……….……………………....42
CHAPTER 4 – Findings………….……………………………………………….......47
CHAPTER 5 – Discussion……...………………...……………………………….....52
REFERENCES……...………………………………………..…………………..………..….63
AUTOBIOGRAPHICAL STATEMENT……………………..…………..……………….......67
ACRONYM LIST……………………………………………..…………………..……………68
APPENDICES
APPENDIX A – Amiodarone Patient Education ………...……………………………..70
APPENDIX B – Amiodarone Clinic Patient Evaluation Protocol……………………….72
APPENDIX C – Amiodarone Clinic Data Collection Tool...…..……………………….73
APPENDIX D – Amiodarone Clinic Code Key…………………..……...………………..75

v

LIST OF TABLES
Table

Page

Table 2.1 Review of Literature…………………………………………………………………..21
Table 2.2 Hierarchy of Evidence……………………………………………………………...23
Table 2.3 Evidence Appraisal………………………………………………………………….24
Table 2.4 HRS Recommended Amiodarone Monitoring Protocol……………………….39
Table 4.1 Group Statistics for Demographics (age, height, weight)…………………………….48
Table 4.2 Group Statistics for Demographics (race, gender)…………………………………….48
Table 4.3 Independent Samples Test for Demographics (age, height, weight)………………...48
Table 4.4 Adherence to Baseline Monitoring Pre and Post Amiodarone Clinic………………...49

vi

LIST OF FIGURES
Figure

Page

Figure 4.1 Percent Adherence to Monitoring Pre-Post Amiodarone Clinic……………………50

vii

ABSTRACT
Evidence shows that patients receiving amiodarone therapy have not adhered to monitoring
guidelines set forth by the Heart Rhythm Society. Uncertainty with responsibility for monitoring
has led to the development of pharmacist-managed or multidisciplinary-managed outpatient
amiodarone clinics. Some limitations have been identified in the pharmacist-managed outpatient
clinics that may be overcome by advanced practice nurse (APN)-managed clinics. The purpose
of this EBP project was to determine what effects an APN-led amiodarone clinic would have on
adherence to amiodarone monitoring guidelines. Using the PICOT format, the clinical question
was developed: Does enrollment in an amiodarone clinic compared with “usual care” change
adherence to monitoring as recommended by best practice guidelines and allow for earlier
recognition of adverse effects of amiodarone to decrease negative patient outcomes over a four
month time period? Using King’s theory of goal attainment and the ACE Star model, guidelines
for monitoring patients newly started on amiodarone therapy were implemented at a northwest
Indiana cardiology practice. Following enrollment, data were collected via chart reviews and
compared to a usual care group which consisted of patients seen in the office during the
previous year who did not receive care based on monitoring guidelines. When the two groups
were compared using the chi-square of independence, a significant difference was found in the
post-amiodarone group for baseline EKG (X2 (1) = 4.56, p = .03). Although results were not
statistically different for baseline TFT (X2 (1) = 1.35, p = .25), LFT, (X2 (1) = 2.55, p = .11), CXR
(X2 (1) = 3.32, p = .07), and PFT (X2 (1) = 1.55, p = .21) diagnostics, those participants in the
post-amiodarone clinic group were more likely to complete the recommended diagnostics. This
small-scale APN-led amiodarone clinic improved amiodarone monitoring adherence leading to
the possibility of future practice of APN-led therapeutic drug monitoring clinics.
Keywords: advanced practice nurse, amiodarone, cardiology, monitoring
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CHAPTER 1
INTRODUCTION
Evidence shows that patients receiving amiodarone therapy for various arrhythmias
have not adhered to monitoring guidelines set forth by the Heart Rhythm Society (HRS),
formerly the North American Society for Pacing and Electrophysiology (NASPE) (Goldschlager
et al., 2007). One reason for this lack of adherence may be the providers’ uncertainty over
responsibility for monitoring amiodarone adverse effects (Dixon, Thanavaro, Thais, & Lavin,
2013). The literature reviewed depicts various outpatient clinics dedicated to the monitoring of
amiodarone according to HRS guidelines (Goldschlager et al., 2007) through pharmacistmanaged practices as well as multidisciplinary practices. Some limitations have been identified
in the pharmacist-managed outpatient clinics that may be overcome by advanced practice nurse
(APN) managed clinics.
Background
Amiodarone is an effective treatment for patients with atrial and ventricular arrhythmias.
Amiodarone is approved by the Food and Drug Administration (FDA) for the treatment of
recurrent, hemodynamically unstable ventricular fibrillation or ventricular tachycardia especially
in patients with structural heart disease, those with left ventricular dysfunction, and those with
recurrent ventricular tachycardia or for the suppression/prophylaxis against atrial fibrillation with
rapid ventricular rates (Goldschlager et al., 2007). Although amiodarone is not FDA-approved
for the treatment of atrial fibrillation, studies have shown that amiodarone has higher rates of
maintaining sinus rhythm at one year compared to other antiarrhythmic medications such as
propafenone and sotalol (Goldschlager et al., 2007). However, amiodarone is not a benign
medication. It has a half-life measured in weeks to months rather than hours and is highly lipidsoluble (Siddoway, 2003). Its lipophilic properties cause amiodarone to be stored in the lungs,
liver, fat, skin, and other organs. Amiodarone also has effects on the gastrointestinal system,
central nervous system, genitourinary system, and ocular system. Absorption from the
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gastrointestinal tract is slow; therefore, it may be months before oral amiodarone reaches its full
therapeutic effect (Dulak, 2005).
Due to its potential for serious adverse effects, the HRS has issued recommendations
for baseline testing and follow-up for those patients on chronic amiodarone therapy
(Goldschlager et al., 2007). Issues related to follow-up include:


The continued assessment of drug efficacy



Titration of drug dose after achieving a steady state; evaluation of adverse and toxic
effects



Appropriate management of toxic effects



Attention to important drug-drug interactions



Attention to important drug-device interactions (Goldschlager et al., 2007, p. 1253).

According to Goldschlager et al. (2007), adverse effects are common, affecting as many as 15%
of patients in the first year of amiodarone therapy and as many as 50% of patients during
chronic amiodarone use. The adverse effects identified by Goldschlager et al. (2007) include
pulmonary reactions (cough, dyspnea), gastrointestinal tract reactions (nausea, loss of appetite,
constipation), thyroid reactions (hypothyroidism, hyperthyroidism), skin reactions (blue
discoloration, photosensitivity), central nervous system reactions (ataxia, paresthesias,
peripheral neuropathy, insomnia, tremors, memory impairment), ocular reactions (halo vision,
disturbance in night vision, photophobia, blurred vision, precipitate deposits), cardiac reactions
(bradycardia, atrioventricular blocks, arrhythmias), and genitourinary reactions (epididymitis,
erectile dysfunction). Due to its highly lipophilic nature and slow absorption through the
gastrointestinal tract, adverse effects may take as long as six months to resolve, necessitating
the duteous follow-up of patients on amiodarone for signs of adverse effects (Goldschlager et
al., 2007).
Statement of the Problem
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For proper care of the patient and minimization of adverse effects of amiodarone,
providers must be aware of the multitude of adverse effects of amiodarone and the
recommended guidelines for monitoring. Per HRS recommendations, patients on amiodarone
should be initially assessed every 3 to 6 months for the first year for rhythm and adverse effects
assessment and every 6 months after the first year (Goldschlager et al., 2007). Often times,
healthcare providers are unsure of who should be following through with the recommended
monitoring (Bickford & Spencer, 2006). An amiodarone clinic managed by an advanced practice
nurse could be a solution to this identified gap in patient care by providing increased adherence
to HRS guidelines for amiodarone monitoring (Goldschlager et al., 2007).
Data from the literature. More than 2 million prescriptions for amiodarone are written
each year for patients (LiverTox, 2014). As many as 93% of these patients (over 1.8 million)
develop some form of adverse reaction to amiodarone (Tafreshi, Chui, & Riley, 2009). These
adverse reactions may be decreased through dose reduction, but as many at 2-26% of patients
(40,000 to 520,000) require discontinuation of amiodarone due to the adverse effects (Tafreshi
et al., 2009). Discontinuation of amiodarone then renders patients vulnerable to the arrhythmia
that amiodarone was prescribed to control unless an alternative can be found. The most feared
adverse drug event is pulmonary toxicity, causing death in about 10% of those diagnosed
(Dulak, 2005).
Amiodarone interacts with multiple medications and multiple classes of medications. The
most serious interactions are with QT prolonging medications, causing further QT prolongation;
digoxin, causing increased and even toxic digoxin levels; and warfarin, causing decreased
warfarin clearance and increased risk of bleeding (Dixon et al., 2013; Dulak, 2009; O’Donovan,
2012; Vassallo & Trohman, 2007).
Research has shown that the implementation of an outpatient drug monitoring clinic for
amiodarone can decrease the severity of the adverse effects and offer earlier recognition and
treatment of the adverse effects by stricter adherence to amiodarone monitoring guidelines
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(Bickford & Spencer, 2006; Snider, Kalbfleisch, & Carnes, 2009; Spence et al., 2011).
Adherence to monitoring guidelines may allow for the continuation of amiodarone therapy, and
research has shown that patient morbidity from such problems as hypothyroidism, loss of vision,
and ataxia and mortality from such problems as pulmonary toxicity have decreased through
earlier recognition and treatment of adverse effects (Sanoski et al., 1998; Snider et al., 2009).
Major adverse amiodarone effects and incidence rates identified in the literature are discussed.
Adverse effects. Patients may experience a variety of adverse events. As many as 93%
of patients on amiodarone therapy develop an adverse drug event (Sanoski et al., 1998;
Tafreshi et al., 2009). These events may be merely problematic such as nausea, difficulty
sleeping, or constipation requiring only amiodarone dose adjustments, to life threatening events
including irreversible pulmonary damage requiring immediate discontinuation of amiodarone
(Sanoski et al, 1998; Tafreshi et al, 2009).
Gastrointestinal. Gastrointestinal adverse drug events include hepatitis, cirrhosis,
nausea, anorexia, and constipation. Clinical findings may include fatigue, weight loss, nausea,
vomiting, hepatomegaly, or the patient may be completely asymptomatic. Incidence rates range
from less than 3% to as much as 30%. (Dulak, 2005; Mackenzie, Syed, Pollak, & Koren, 2011;
Vassallo & Trohman, 2007).
Dermatologic. Dermatological findings may include bluish discoloration to the skin or
photosensitivity. These clinical findings are seen with sun-exposed skin and occur in less than
10% of patients to as many as 75% of patients (Dulak, 2005; Mackenzie et al., 2011; Vassallo &
Trohman, 2007).
Ocular. Corneal deposits can occur in as many as 90% of patients. Patients may also
experience halo vision (less than 5%), poor visual acuity, or less often, changes in peripheral
vision due to optic neuropathy (Dulak, 2005; Mackenzie et al., 2011; Vassallo & Trohman,
2007).
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Central nervous system. Peripheral neuropathy is experienced in 0.3% of patients
whereas 3-30% of patients may experience ataxia, tremors, and sleep disturbances such as
insomnia (Dulak, 2005; Mackenzie et al., 2011; Vassallo & Trohman, 2007).
Thyroid. Around 3% of amiodarone is comprised of iodine, leading to thyroid
dysfunction in some patients caused by the inhibition of the de-iodination of T4 to T3
(O’Donovan, 2012; Vassallo & Trohman, 2007). Hyperthyroidism and hypothyroidism may occur
in over 30% of patients taking amiodarone with hypothyroidism being more common. Symptoms
may include weight loss, malaise, goiter, tremors, cold intolerance, hair loss, bradycardia, and
tachycardia (Dulak, 2005; Mackenzie et al., 2011).
Cardiac. Around 5% of patients may experience bradycardia when taking amiodarone
manifested by fatigue or syncope (Dulak, 2005; Mackenzie et al., 2011). Rarely patients may
experience arrhythmias related to amiodarone use such as torsades de pointes or
atrioventricular block (Dulak, 2005; Mackenzie et al., 2011).
Pulmonary. A potentially life-threatening complication of amiodarone therapy is
amiodarone-induced pulmonary toxicity. Incidence rates range from 5-13% and mortality rates
range from 10-23% (Ernawati, Stafford, & Hughes, 2008). Clinical findings may include acute
onset of shortness of breath, nonproductive cough, chest pain, weight loss, and fever (Dulak,
2005; Mackenzie et al., 2011). Patchy infiltrates may be present on chest x-ray (O’Donovan,
2012).
Drug/food interactions. Amiodarone is metabolized by the cytochrome P450 system in
the liver (Mackenzie et al., 2011) and may interact with multiple medications including warfarin;
digoxin; beta-blockers; calcium channel blockers; cyclosporine; antidepressants including
selective serotonin reuptake inhibitors and tricyclics; antimicrobials such as macrolides, azole
antifungals, fluoroquinolones; other antiarrhythmics such as quinidine, disopyramide,
procainamide, flecainide, and sotalol; and statins (Dulak, 2005; Mackenzie et al., 2011;
O’Donovan, 2012; Vassallo & Trohman, 2007). Patients should also be instructed to avoid
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grapefruit juice due to its inhibition of the cytochrome P450 pathway leading to increased levels
of amiodarone in the blood (O’Donovan, 2012).
Research identification of adherence to amiodarone monitoring. Monitoring for
amiodarone therapy is essential for early recognition and treatment of adverse effects. Bickford
and Spencer (2006) conducted a study to assess baseline amiodarone monitoring adherence
on hospital inpatients and adherence to continued amiodarone monitoring adherence as
outpatients. Baseline monitoring for liver function tests, thyroid function tests, and chest x-rays
was 87%, 82%, and 87% respectively. However, only 24% of the patients received baseline
pulmonary function testing with only half of those including the diffusion capacity (Bickford &
Spencer, 2006). As outpatients, only 35% of patients received liver function testing every six
months, only 20% of patients received thyroid function testing every six months, and only 50%
of patients received yearly chest x-rays (Bickford & Spencer, 2006).
Stelfox et al. (2004) conducted a similar study to assess baseline amiodarone monitoring
adherence. The researchers found that 52% of patients had baseline pulmonary function testing
completed, 42% had baseline liver function testing, 40% had baseline thyroid function testing,
85% had baseline electrocardiograms, and 60% had baseline chest x-rays (Stelfox et al., 2004).
Amiodarone adverse drug events were identified in 8% of the patients during this monitoring
period with approximately one-third of the adverse drug events deemed to be preventable with
greater adherence to amiodarone monitoring guidelines (Stelfox et al., 2004).
Success of amiodarone clinics. One of the best methods of decreasing potential
adverse effects of amiodarone therapy is the use of a dedicated clinic. Sanoski et al. (1998)
completed a study comparing amiodarone monitoring in patients before and after referral to a
multidisciplinary amiodarone clinic. This multidisciplinary team consisted of an
electrophysiologist, a clinical pharmacist, a cardiovascular pharmacy fellow, and
electrophysiology nurse. The electrophysiologist’s responsibilities included acting as medical
director and overseeing the other team members and authorizing amiodarone dose
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adjustments. The responsibilities of the clinical pharmacist, cardiovascular pharmacy fellow, and
electrophysiology nurse included objective and subjective patient assessment, amiodarone drug
interaction screening, patient/staff education, and scheduling/interpretation of diagnostic testing
(Sanoski et al., 1998). Before enrollment in the amiodarone clinic, only 23% of the patients had
the appropriate laboratory tests performed by primary physicians with improvement to 90% once
the patients were enrolled into the multidisciplinary amiodarone clinic (Sanoski et al, 1998).
In 2004, Graham and colleagues conducted a similar study assessing amiodarone
adherence rates in patients enrolled in an amiodarone monitoring clinic. This clinic was
pharmacist-managed, rather than managed by a multidisciplinary team. Adherence to baseline
monitoring improved for thyroid function testing, liver function testing, eye exams, and
electrocardiograms, but not for pulmonary function testing and chest x-rays (Graham et al.,
2004).
Snider et al. (2009) conducted a study comparing a pharmacist-led antiarrhythmic
monitoring service with usual care. Before referral to the antiarrhythmic monitoring service, the
researchers found that only 59% of patients had completed all the recommended diagnostic
testing, but after enrollment into the antiarrhythmic service, 98.5% of patients had completed all
of the recommended diagnostic testing (Snider et al., 2009).
Johnson and colleagues (2010) conducted a similar study comparing a pharmacist-led
amiodarone monitoring service to usual care. After enrollment into the amiodarone monitoring
service, percentage of adherence both at baseline and for continuing monitoring increased in all
areas of diagnostics except for chest x-rays (Johnson et al., 2010). Spence et al. (2011)
organized a similar study examining amiodarone monitoring adherence between those enrolled
in the pharmacist-managed amiodarone monitoring clinic and those in usual care. Adherence
was higher in the pharmacist-managed amiodarone clinic group for baseline and continued liver
function testing, thyroid function testing, chest x-rays, and pulmonary function testing (Spence et
al., 2011).
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Spence et al. (2011) organized a study examining amiodarone monitoring adherence
between those enrolled in the pharmacist-managed amiodarone monitoring clinic and those in
usual care. Adherence was higher in the pharmacist-managed amiodarone clinic group for
baseline and continued liver function testing, thyroid function testing, chest x-rays, and
pulmonary function testing (Spence et al., 2011).
APN-led clinics. To date, no APN-led amiodarone/antiarrhythmic clinics were
documented in the literature. However, other APN-led clinics for chronic disease/medication
management have been successful. Chandler (2007) explored the use of a nurse-led clinic to
reduce readmission rates for asthma. Readmission rate decreased from 22% to about 6% after
enrollment into the nurse-led asthma clinic post hospital discharge. Hatchett (2005) outlined
eight roles of a nurse-led clinic. These roles include “educating patients, providing psychological
support and explanation, monitoring the patient’s condition, conducting physical assessments,
ordering appropriated diagnostic investigations and interpretation, creating treatment plans,
often involving other members of the multidisciplinary teams, such as GPs or primary care
colleagues, managing medicines, empowering the patient or carer to achieve greater selfmonitoring and/or care” (Hatchett, 2005, p. 50). Patients with heart failure have also been
successfully managed by nurses (Grange, 2005). Evaluation of nurse-led heart failure clinics
demonstrated an improved quality of life, individualized care, appropriate medication
management, and improved patient education as well as reduced readmission rates (Grange,
2005). A nurse-led acute coronary syndromes clinic was found to have a significantly lower sixmonth readmission rates (Alfakih et al., 2009).
Nurses have also been used in medication management. In a 2012 study, Levine, Shao,
and Klein compared a nurse-led warfarin monitoring service to the usual care of monitoring by a
family physician. They found that nurse-led monitoring of warfarin was just as effective as
physician monitoring (Levine et al., 2012). Aziz, Corder, Wolffe, and Comerota (2011) found that
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a lower percentage of patients monitored by the anticoagulation service that was nurse-led
required hospitalization and provided a significant cost savings.
Data from the clinical agency. The clinical agency for this EBP project was a
cardiology practice in northwest Indiana. The electrophysiologist employed by the practice
expressed concern that adherence to amiodarone monitoring could use significant improvement
(N. Nasser, personal communication, June, 2013). Currently, approximately sixty patients within
the electrophysiology practice are on amiodarone therapy. At the clinic, all patients newly
initiated on amiodarone receive baseline thyroid/liver function testing, a baseline
electrocardiogram, a baseline chest x-ray, a baseline pulmonary function test, and a baseline
eye exam. Patients on chronic amiodarone therapy receive biannual liver/thyroid function
testing, a yearly electrocardiogram, and a yearly chest x-ray. Some patients lost to proper
amiodarone follow-up were identified by the project manager and the electrophysiologist as
having adverse effects of amiodarone including liver toxicity demonstrated by severely elevated
liver function tests, pulmonary toxicity demonstrated by abnormal chest CT scans and abnormal
pulmonary function tests, and hypothyroidism as demonstrated by elevated TSH levels. It was
decided by the electrophysiologist that implementing an amiodarone clinic would increase
adherence to amiodarone monitoring guidelines and allow for increased use of amiodarone in
the practice for treatment of arrhythmias (N. Nasser, personal communication, June, 2013).
A small-scale amiodarone monitoring clinic was initiated in August, 2013 to explore the
benefit of an APN-led amiodarone clinic within the cardiology practice. A protocol for
amiodarone monitoring was developed by the electrophysiologist using HRS guidelines
(Goldschlager et al., 2007). Patients were educated on the risks and benefits of amiodarone use
as well as the amiodarone monitoring schedule by the electrophysiologist and electrophysiology
nurse, also serving as the EBP project manager. A patient education sheet was created
educating patients about common adverse effects of amiodarone and the more dangerous
effects including pulmonary toxicity. Also included on the patient education sheet was the
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amiodarone monitoring schedule and the office number to call if any adverse effects were
observed by patients. A more intense follow-up was conducted by the electrophysiology nurse
to observe for both subjective and objective signs and symptoms of adverse amiodarone
effects.
Purpose of the EBP Project
The purpose of this evidence-based practice (EBP) project was to assess if enrollment in
an APN-led amiodarone clinic would change adherence to amiodarone monitoring
recommended by best practice guidelines. Furthermore, it was hoped any adverse effects would
be recognized in a timely manner to allow for earlier intervention to prevent patient morbidity
and mortality from amiodarone adverse effects.
Identification of the compelling clinical question. The compelling clinical question
that was hoped to be answered by this EBP project is: Does enrollment in an amiodarone clinic
compared with “usual care” change adherence to monitoring as recommended by best practice
guidelines and allow for earlier recognition of adverse effects of amiodarone to decrease
negative patient outcomes over a four month time period?
PICOT format. This EBP project used the PICOT format to formulate the compelling
clinical question (Melnyk & Fineout-Overholt, 2011). This format included the components of:


(P)atient population or disease of interest. In this project, the population of interest is
those patients with newly initiated amiodarone therapy who are 18 years of age or older.



(I)ntervention or issue of interest. The patients enrolled in the amiodarone clinic based
on HRS guidelines (Goldschlager et al., 2007) for the monitoring of amiodarone is the
intervention of interest.



(C)omparison intervention or issue of interest. Those patients identified by chart review
as the “usual care” group will be the comparison group.
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(O)utcome. The outcomes of monitoring adherence, identification of adverse drug
events, and decreased negative outcomes are of interest.



(T)ime. The time period proposed was from September 1, 2013 to December 31, 2013.

Significance of the Project
Outpatient medication management clinics can be useful in monitoring those patients on
medications which require more intense monitoring (Tafreshi et al., 2009). Subjective patient
data can be gathered at each visit and added to the objective assessment to develop an
assessment and plan of action to promote the best patient outcome for patients on amiodarone
therapy (Earl & Reinhold, 2014). In order to build a strong outpatient medication management
clinic, a strong therapeutic relationship must be built, patient health knowledge must be
ascertained, and medication adherence must be evaluated (Earl & Reinhold, 2014). These are
all practices that an APN is more than qualified to perform as depicted within the role
components of clinician, consultant, educator, leader, and researcher which promote change,
communication, critical thinking, and lifelong learning.
Nurse-led clinics are not new to healthcare, with nurse-led clinics already established in
the care of patients with congestive heart failure (Grange, 2005), patients with heart disease
(Hatchett, 2005), and patients with liver disease (McAfee, 2012), just to name a few. APNs can
provide valuable care through clinical skills that offer symptom relief, facilitation of
interdisciplinary referrals (McAfee, 2012), as well as provide improved outcomes for patients as
demonstrated by fewer hospital readmissions (Grange, 2005). These tasks are completed by
the APN through the education of patients regarding their chronic conditions (Grange, 2005;
McAfee, 2012).
The design of this EBP project was created to show that enrollment into a nurse-led
amiodarone clinic would enhance patient care within a specific cardiology practice and result in
increased adherence to monitoring guidelines. Through adherence to recommended monitoring
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guidelines, earlier recognition and treatment of adverse drug events of amiodarone would take
place to decrease negative outcomes that may be experienced if otherwise left untreated.
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CHAPTER 2
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE
This chapter includes the theoretical framework, evidence-based practice model, and
review of literature used for guidance of the project. This project uses Imogene King’s Theory of
Goal Attainment (King, 1971) as a theoretical framework and the ACE Star Model of Knowledge
Transformation (Stevens, 2004) for the Evidence-Based practice model. The search engines
used as well as the keywords and inclusion/exclusion criteria will also be discussed in this
chapter. Once the review of literature was completed, the sources of evidence chosen were
critically appraised to provide sustenance to the EBP project and provide guidelines for the use
of an APN-led amiodarone clinic in the outpatient setting.
Theoretical Framework
Description and application of the model. In her book, Toward a Theory for Nursing:
General Concepts of Human Behavior, Dr. King (1971) expressed the need for the
establishment of a conceptual framework for nursing. With the explosion of evidence-based
practice, the organization of key concepts became important, both in the advancement of
clinical practice and in the education of future nurses. Some sort of harmony was needed
between those responsible for patient care and those responsible for advancing research for
clinical practice. From this, Dr. King developed her conceptual framework for nursing (King,
1971). This framework consists of three dynamic systems (individual, group, and society)
interacting with one another. The center of Dr. King’s conceptual framework consists of the
personal system. This would be the individual, or patient, that the nurse interacts with. The
patient is oriented toward achievement of goals in a dynamic manner through the guidance of
nursing (King, 1971; King, 1981). For the purposes of this EBP project, the personal system will
consist of the individual patient needing therapy in an APN-led clinic.
The individual interacts with others to form the interpersonal system. This part of the
conceptual framework focuses on interactions that take place between the patient and those
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assisting with goal attainment. The patient participating in the EBP project will interact with the
EBP project manager to achieve a common goal.
The social system includes those individuals who share common goals and interests
(Sieloff-Evans, 1991). Examples include families, religious groups, educational organizations, or
governments (King, 1999). The social groups that patients are a part of often influence the
patient’s perceptions. For the purposes of the EBP project, the social system might include
whomever the patient will bring with them to the follow-up appointments with the EBP project
manager. This might include family members or friends.
The personal system encompasses the individual. Individuals interact with one other to
form small groups called interpersonal systems. Groups with similar interests and goals come
together to form organized structures, such as families and societies, called social systems
(King, 1981). Several assumptions exist within this conceptual framework. First, human beings
are considered to be dynamic, open systems. This allows for constant action within the
environment and reaction to the environment. Nursing’s focus is the interaction of patients within
their individual environment, taking into account the perceptions each individual has of the
environment in which they live. The common goal between nursing and the individual is to
obtain or maintain health (Frey et al., 2002; King, 1971; King, 1981). Once individuals attain
health, individuals have the ability to function appropriately within their societal role (Whelton,
1999).
In this nursing theory, nurses and patients come together, communicate information, set
mutual goals, and take appropriate actions to attain the mutual goals. A new definition for
nursing was created during the construction of the theory stating “nursing is a process of human
interactions between nurse and client whereby each perceives the other and the situation; and
through communication, they set goals, explore means, and agree on means to achieve goals”
(King, 1981, p. 144). This new definition allowed for further expansion of patient-involvement in
the development of treatment plans taking into account patient-individualized stressors and
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obstacles to optimal health. In summary, the nurses and patients interact and move toward a
common goal through the nursing process taking into account different perceptions (views) of
the environment around them, different roles (position within the patient’s social system), and
stress (exchange of energy between the patient and their environment) through communication
(trade of information) and transaction (series of negotiations) (King, 1981). King purposefully
included patients in the treatment process and encouraged them to become a part of the
treatment plan process. Goal attainment is useful in nursing as it allows for easy validation of
the nursing process. Goal attainment is an easily measured outcome that provides evidence of
the usefulness of the nursing process and nursing interventions through completion of the
mutually agreed upon goal between nurses and patients. Both patients and nurses interact and
form a relationship to better understand one another, develop mutual goals, and develop a
process to obtain the set goals. Both parties within the dynamic interpersonal relationship
contribute to goal attainment and processes to obtain mutual goals.
Application of the theoretical framework to EBP project. In this EBP project,
improvement in amiodarone monitoring became the common goal for achievement by patients
and the EBP project manager. Patients were the personal system. Once patients attended the
first appointment with the EBP project manager, an interpersonal system was established.
Through transactions as well as education of amiodarone adverse effects, the EBP project
manager and patients decided on the mutually agreed upon goal of adherence to amiodarone
monitoring guidelines to promote the best possible outcome of patients. Those participating in
the patients’ care, such as family members or friends, became part of the social system,
influencing the process to achieve goal attainment.
Theoretical framework strengths and weaknesses. The strengths of this framework
include its ease in adaptability to a broad range of interpersonal relationships encompassing a
wide range of disciplines throughout the patient care process. The APN can utilize goal
attainment in the care of a multitude of chronic and acute conditions such as heart failure, liver
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disease, and cardiac disease. The major limitation of this framework is the dependence on the
interpersonal relationship. A strong therapeutic relationship must be built to establish the trust
needed by patients to facilitate mutually agreed upon goals. The successful outcome of goal
attainment must be mutually agreed upon by each party in the interpersonal relationship.
Without agreement and participation, goal attainment will not be achieved. In the case of the
amiodarone clinic, the mutual goal is improved adherence to amiodarone monitoring guidelines.
Improved monitoring adherence is achieved through patient compliance with monitoring. Patient
compliance with diagnostic monitoring is accomplished through patient education on the
importance of amiodarone monitoring adherence. The common goal of increased adherence to
amiodarone monitoring allows for early identification of potential adverse drug events.
Evidence-Based Practice Model
Description and application of the EBP model. The ACE Star Model was chosen to
guide this evidence-based practice project. The model originated at the University of Texas
Academic Center for Evidence-Based Practice (ACE) (Stevens, 2004). The goals of this
university-based program include improving patient outcomes, improving patient care, and
improving patient safety. The objectives of ACE are to (a) advance nursing roles in the
synthesis of evidence, translation, incorporation, and improvement science; (b) furnish a
location for interdisciplinary evidence-based practice; (c) simplify transfer of health care
knowledge to nursing and health care practice; (d) inspire, enable, organize, and conduct
research and interdisciplinary inquiries in the field of evidence-based practice and quality
improvement; (e) and offer education in evidence-based practice through the entire spectrum of
collegiate programs as well as continuing education programs (Stevens, 2004). The ACE
framework organizes evidence-based practice processes into a five-point star which illustrates
the five stages of the models including discovery of research, evidence summary, translation to
guidelines, practice integration, and evaluation (Stevens, 2004).
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Stage 1: Discovery of research. In this stage of the ACE Star Model, original
knowledge is exposed through research and scientific inquiry (Stevens, 2004). Results are
generated through single studies which can range from descriptive to correlational to causal and
from randomized control trials to qualitative studies. The purpose of this stage is to build the
mass of research regarding clinical activities.
Many patients on amiodarone have not adhered to recommended monitoring guidelines
(Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006;
Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al, 2009). Several
studies were identified through a review of literature documenting the success of amiodarone
clinics to improve adherence to monitoring guidelines (Graham et al., 2004; Johnson et al.,
2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi
et al., 2009). By using discovery of research, knowledge regarding the usefulness of
amiodarone clinics in adherence to monitoring guidelines was obtained.
Stage 2: Evidence summary. The mass of research is combined into a single,
significant statement. Systematic reviews are often developed in this stage as well as the
identification of bias and effects of chance (Stevens, 2004). Evidence summary also allows for
the recurrent update of knowledge with fresh evidence.
Within the current evidence, the use of outpatient amiodarone clinics has shown
improvement in adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 2010;
Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al,
2009) and the earlier discovery of adverse effects of amiodarone (Johnson et al., 2010; Sanoski
et al., 1998; Snider et al., 2009; Tafreshi et al., 2009). Most of the current research utilizes
outpatient clinics run by pharmacists. Some amiodarone clinics were run by a multidisciplinary
team including pharmacists, physicians, and nurses. The use of an APN-led clinic was designed
to overcome barriers reported by the pharmacist-led amiodarone clinics.
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Stage 3: Translation to guidelines. Translation permits evidence delivery into a
summary of useful, relevant information termed clinical practice guidelines. This evidence may
be located in care standards, clinical pathways, organizational protocols, and organizational
algorithms. These guidelines represent evidence-based practices to support clinical decisionmaking. Evidence is coupled with clinical expertise and theory to allow for the application of the
evidence across a multitude of patient populations and settings (Stevens, 2004).
Many large healthcare organizations (Johnson et al., 2010; Raebel et al., 2006; Snider et
al., 2009; Spence et al, 2011) have instituted outpatient drug monitoring programs to increase
adherence to monitoring guidelines and increase the identification of adverse drug effects.
These monitoring programs have provided data that show increased adherence to monitoring
guidelines and the early identification of adverse drug effects. By having a monitoring program
dedicated to amiodarone monitoring by HRS guidelines, the confusion regarding who was
responsible for monitoring these patients was negated and allowed for the early identification of
adverse drug effects requiring dose adjustments or possibly discontinuation of amiodarone
(Goldschlager et al., 2007). Multidisciplinary amiodarone clinics as well as pharmacist-led clinics
have been documented in the literature.
Stage 4: Practice integration. Society expects healthcare professionals to remain upto-date on current best practices. In order to complete this task, healthcare professionals and
organizations must be willing to accept new guidelines for practice if the evidence is supportive
of the change (Stevens, 2004).
This EBP project utilized a chart review of patients prior to institution of an amiodarone
clinic in a small northwestern Indiana cardiology practice and then another chart review of
patients after implantation of an amiodarone clinic. Baseline monitoring as well as continuation
of monitoring for those on chronic amiodarone therapy was compared between these two
cohorts.
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Stage 5: Evaluation. Evaluation is the final step in the ACE Star Model (Stevens, 2004).
The influence of evidence-based practice on patient outcomes, healthcare professional/patient
satisfaction, efficacy/efficiency of care, economic analysis, and health status impact were
evaluated. For this EPB project, outcomes evaluated included the number of participants that
completed baseline diagnostic monitoring for those newly initiated on amiodarone and the
number of participants that completed continuation of monitoring for those on chronic
amiodarone therapy.
Previous studies and reviews have suggested an increase in the adherence to
monitoring guidelines (Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski
et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009) and the identification
of adverse effects of amiodarone allowing for early treatment to reduce morbidity and mortality
from the adverse effects of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al.,
2009; Tafreshi et al., 2009). It was hoped that these results would be duplicated in this EBP
project.
Strengths and limitations of the EBP model. Strengths of the ACE Star model include
the step-by-step progression of the EBP process outlined in five-points that flows logically from
the start of EBP in the review of literature to the end where evaluation of the EBP process
occurs. As movement occurs through the ACE Star model, the applicability of research to
nursing practice strengthens. Research that has accumulated in an area has been reviewed,
summarized, and transmitted to practice with evaluation of the implementation of the EBP. A
more succinct summary along with consistent research that is summarized allows for a more
meaningful research review and permits the research to be applicable to many different areas of
nursing. A limitation of the ACE Star model includes the dependence on the availability of
research literature regarding the proposed EBP project. Without available research, the EBP
process becomes stalled at Stage 1 (Discovery of research). A lack of research pertaining to
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APN-led amiodarone clinics was observed, requiring the expansion of the literature search to
include any form of nurse leadership of amiodarone clinics for this EBP project.
Review of Literature
Literature review. Multiple sites were used in this literature review including the
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Medline, ProQuest, the
Joanna Briggs Institute, the Cochrane Library, Academic Search Premier, the Virginia
Henderson International Nursing Library, and GoogleScholar (see Table 2.1). A review of the
literature was completed using the keywords of “amiodarone, monitoring, and toxicity” which
yielded 6 results in a CINAHL search. Medline was searched using the limiters of publication
dates from 1995-2013, English language and the keywords of “amiodarone and monitoring”
which yielded 286 results. Adding the limiter of toxicity yielded 42 results. A ProQuest search
using the limiters of publications dates from 2000-2013, English language, peer reviewed, and
the keywords of “amiodarone, toxicity, and monitoring” yielded 445 articles. A search of the
Cochrane Library using amiodarone yielded 3 results, antiarrhythmic yielded 2 results, and
antiarrhythmic clinic yielded 13 results. A search of the Joanna Briggs Institute using the
keyword of amiodarone yielded no results, antiarrhythmic yielded no results, and outpatient
yielded 3 results. One article was found using a hand search of journal publications available in
the clinic where the project manager is employed. A search using GoogleScholar using the
keywords of amiodarone, monitoring, toxicity, ambulatory, clinic, and multidisciplinary using the
limiter of publication dates from 2003-2013 yielded over 600 results, 15 of which were
applicable to this EBP project using the inclusion criteria listed below and were duplicates from
the above search engines. Two additional articles were found through a reference list search of
applicable articles included in this EBP project. The limiters used were expanded and narrowed
depending on the number of results received to allow for more specificity in the review of
literature pertaining to the EBP project.
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Table 2.1
Review of Literature
Database

CINAHL

Medline

ProQuest

Joanna Briggs
Institute

Cochrane
Library

Academic
Search Premier
Virginia
Henderson
International
Nursing Library
Articles found
through
reference list
search

GoogleScholar

Keywords Used

Limiters
Used

amiodarone,
monitoring,
toxicity

English
language,
Scholarly
Journals

amiodarone,
monitoring

English
Language,
Publication
dates from
1995-2013
English
language,
publication
dates from
20002013, peer
reviewed

Added the
keyword toxicity
amiodarone,
monitoring,
toxicity

amiodarone
antiarrhythmic
outpatient clinic
amiodarone
antiarrhythmic
antiarrhythmic
clinic
amiodarone,
monitoring,
toxicity

Total
Relevant Duplicates
Results
to
Project
6
2
1

Included in
Project
1

286

13

13

13

42

9

9

0

445

1

1

0

0
0
3
3
2
13

0
0
0
0

0
0
0

0
0
0
0
0
0

18

5

5

0

amiodarone

3

0

0

0

antiarrhythmic
ambulatory care

9
9

0
0

0
0

0
0

English
language,
Scholarly
Journals

2

amiodarone,
monitoring,
toxicity,
ambulatory,
clinic,
multidisciplinary

617
published
from 20032013

15

14

1
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Abstract review. The abstracts of the articles were reviewed during the literature search
for inclusion and exclusion criteria. The inclusion criteria included (a) overall scientific value, (b)
adult subjects, (c) relevance to the EBP project, (d) publication after 2003, (e) studied
amiodarone/drug monitoring, (f) written in English, and (g) utilized HRS amiodarone monitoring
guidelines (Goldschlager et al., 2007). After review of several studies that adhered to the
inclusion criteria, the publication date limiter was extended to include articles from 1995-2003 to
allow for the inclusion of some of the first studies of amiodarone clinics. The study by Sanoski
and colleagues (1998) included laid the foundation for amiodarone clinics, incorporating a
multidisciplinary team in the structure of the amiodarone clinic. Factors that excluded studies
from inclusion in the EBP project included (a) poor data quality, (b) written in a foreign language,
(c) did not use amiodarone within the study, (d) used subjects under the age of 18, and (e) did
not use HRS guidelines in the monitoring protocol (Goldschlager et al., 2007). After reviewing
the full text of the articles that met inclusion criteria and removing the duplicates, 17 articles
were identified for use in this EBP project. The 17 sources included 7 research studies, an
expert committee practice guideline for amiodarone monitoring, and 9 articles discussing
background amiodarone information including mechanism of action, use, adverse effects, and
interactions. Nine additional articles were added to solidify the usefulness of APN-led clinics.
Describe levels of evidence. Polit and Beck’s (2012) Evidence Hierarchy was used for
this EBP project (see Table 2.2). This hierarchy describes seven levels of evidence based on
the strength of evidence provided. At the top of the hierarchy representing Level I evidence are
systematic reviews of randomized control trials (RCTs) and systematic reviews of
nonrandomized trials. Level II evidence includes single randomized control trials (RCTs) and
single non-randomized trials. Systematic reviews of correlational/observational studies comprise
Level III evidence. Single correlational or observational studies represent Level IV evidence.
Level V evidence includes systematic reviews of descriptive, qualitative, or physiologic studies.
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Single descriptive, qualitative, or physiologic studies signify Level VI evidence. At the bottom of
this hierarchy are expert opinions of evidence representing Level VII evidence.
Table 2.2
Hierarchy of Evidence
Hierarchy of evidence (Polit & Beck, 2012)
Level I:
a. Systematic review of randomized controlled trials
(RCTs)
b. Systematic review of non-randomized trials
Level II:
a. Single RCT
b. Single nonrandomized trial
Level III:
Systematic review of correlational/observational studies
Level IV:
Single correlational/observational study
Level V:
Systematic review of descriptive/qualitative/physiologic
studies
Level VI:
Single descriptive/qualitative/physiologic study
Level VII:
Opinions of authorities, expert committees

Articles included in
project
0

1(a)
0
5
0
1
1

Appraise relevant evidence. Once the review of literature was obtained and articles
were chosen that met inclusion criteria, a thorough appraisal was completed on each source of
evidence used for the EBP project. These appraisals were completed utilizing guidelines as
outlined by Melnyk and Fineout-Overholt (2011). The appraisal tools included the Rapid Critical
Appraisal Checklist for Randomized Clinical Trials, the Rapid Critical Appraisal Checklist for
Cohort Studies, the Rapid Critical Appraisal Checklist for Qualitative Evidence, and the Rapid
Critical Appraisal Checklist for Evidence-Based Clinical Practice Guidelines (Melnyk & FineoutOverholt, 2011) (see Table 2.3).
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Table 2.3
Evidence Appraisal
Citation

Purpose

Sample

Design

Measurement

Bickford, C. L.
& Spencer, A.
P. (2006).

Quantification of
adherence to
published
recommendations
for baseline
monitoring when
initiating inpatient
amiodarone
therapy at a
university teaching
hospital and
determine whether
appropriate serial
monitoring of
chronic
amiodarone
therapy is
occurring in the
outpatient setting.

45 patients
admitted as
inpatients at
the Medical
University of
South
Carolina
(MUSC) who
received
amiodarone
between
November 1,
2003 and
March 31,
2004.

Retrospective
review of
medical
records

45 inpatients had
their medical
record reviewed
to identify whether
baseline liver
function tests
(LFTs), thyroid
function tests
(TFTs), chest xray (CXR), and
pulmonary
function tests
(PFTs) were
completed.

20 patients
with an
MUSC
outpatient
provider who
had received
amiodarone
therapy for at
least 6
months.

20 outpatients
had medical
records reviewed
to evaluate if
baseline LFTs,
TFTs, CXR, and
PFTs were
completed and
the number of
patients who had
received LFTs
and TFTs every 6
months, and
yearly CXRs.

Results/Findings
Inpatients- 87%
received baseline
LFTs, 82% received
baseline TFTs, 87%
received baseline
CXRs, and 24%
received PFTs.
Outpatients - 95%
had received baseline
LFTs, 75% had
received baseline
TFTs, 75% had
received baseline
CXRs, and 30% had
received baseline
PFTs. Only 35% of
patients had LFTs
every 6 months, 20%
of patients had TFTs
every 6 months, and
50% of patients had
yearly CXRs.

Evidence Level
and Appraisal
Level VI
Data review
was limited to
available files
and did not
include outside
records.
Descriptive
statistics were
applied to
obtain
adherence to
monitoring and
results
collected are
similar to other
studies,
indicating a
need for
dedicated
amiodarone
clinics.
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Goldschlager,
N., Epstein, A.
E., Naccarelli,
G. V.,
Olshansky, B.,
Singh, B.,
Collard. H. R.,
& Murphy, E.
(2007).

Recommendation
for amiodarone
diagnostic
monitoring

Clinical
practice
guideline with
approval by
the HRS
Board of
Trustees

25
Level VII
Based on
evidencebased
data/clinical
experience.
Research
funding not
reported.
Literature is
included within
one year of
publication.
Levels of
evidence were
not identified.
Amiodarone
monitoring
guidelines are
discussed with
treatment of
adverse events
and need for
referral
allowing for
easy
completion by
providers.
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Graham, M.
R., Wright, M.
A., & Manley,
H. J. (2004).

To determine
whether
adherence to
monitoring
guidelines
improved as a
result of the
development and
implementation of
an amiodarone
monitoring clinic
(AMC).

225 patients
were
included in
this study 154 in the
intervention
group and 71
in the control
group.

Retrospective
cohort study

26
Those patients in
the intervention
(pharmacistmanaged
program) cohort
and the usual
care cohort were
compared for
adherence to
testing during the
12 months after
the initiation of the
AMC.

For baseline
diagnostics, the AMC
improved compliance
for some of the
diagnostics.
AMC
- PFT - 12%
- CXR - 18%
- TFT - 36%
- LFT - 40%
- Eye Exam - 30%
- EKG - 41%
Usual Care
- PFT - 15%
- CXR - 24%
- TFT - 32%
- LFT - 31%
- Eye Exam - 15%
- EKG - 32%
The AMC improved
compliance with 2 of
the 3 continued
monitoring guidelines.
AMC
- TFTs - 66%
- LFTs - 69%3.
Usual care
- TFTs - 37%
- LFTs - 38%
- EKG monitoring was
not shown to be
significantly improved
by the AMC

Level IV
Follow-up was
sufficient to
give data for
the
amiodarone
clinic cohort
and a specific
timeline is
discussed. The
diagnostics
completed
were objective
to remove
bias, leading to
valid study
results.
Statistical
testing was
completed to
compare
demographic
data and
adherence to
baseline as
well as
continued
amiodarone
monitoring.
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Johnson, S.
G., Canty, K.,
Billups, S., &
Schimmer, J.
(2010).

To determine
whether patients
enrolled in a
centralized
amiodarone
monitoring service
(AMS) were more
adherent to
amiodarone
monitoring
guidelines and
To determine if the
incidence of
amiodaronerelated toxicity
differed for
patients enrolled in
the AMS.

905 patients
were
included in
the study 518 in the
control
cohort and
387 in the
AMS cohort.

Retrospective
longitudinal
cohort design

27
Control and AMS
cohorts were
compared in
regards to
baseline liver
function tests
(LFTs), thyroid
function tests
(TFTs), chest xray (CXR), and
electrocardiogram
(EKG) and
appropriate
follow-up interval
testing

Baseline testing
Control cohort
LFTs 44%, TFTs
49%,CXR 56%, EKG
58%
AMS cohort
LFTs 69%, TFTs
55%,CXR 45%, EKG
76%
6 month follow-up
testing
Control cohort
LFTs 76%, TFTs 70%
AMS cohort
LFTs 86%, TFTs 74%
1 year follow-up
testing
Control cohort
LFTs 69%, TFTs
64%,CXR 71%, EKG
75%
AMS cohort
LFTs 84%, TFTs
68%, CXR 53%, EKG
89%.
Statistical significance
was found in LFT and
EKG monitoring only.

Level IV
Follow-up was
sufficient to
give data for
the
amiodarone
clinic cohort
and a specific
timeline is
discussed.
Objective
diagnostics
removed bias,
Statistical
testing was
completed to
compare
demographic
data and
adherence to
baseline as
well as
continued
amiodarone
monitoring.
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Raebel, M. A.,
Chester, E.
A., Newsom,
E. E., Lyons,
E. E.,
Kelleher, J.
A…Magid, D.
J. (2006).

To determine if
using an electronic
tool effectively
increases the
percentage of
patients receiving
laboratory
monitoring during
ongoing drug
therapy.

All adult
members of
the
outpatient
KaiserPermanente
Colorado
medical
offices were
eligible for
the study.
Patients
were
included in
the study if
taking at
least one of
the study
medications.
A total of
9139
patients were
included.

Randomized
trial

28
Usual-care group
(control group)
was compared to
the intervention
group. The
intervention
consisted of an
electronic alert to
pharmacists that a
lab result was
missing based on
established
guidelines.
Pharmacists then
ordered missing
lab tests,
reminded patients
to undergo tests,
reviewed lab
results and
managed any
abnormal results.

For amiodarone, 71%
of patients in the
intervention group
versus 55% of
patients in the control
group were
appropriately
monitored according
to guidelines
representing
significant
improvement in
amiodarone
adherence.

Level IIa
Participants
were randomly
assigned,
random
assignment
was concealed
to participants
and providers,
and groups
were similar
based on
statistical
testing. It was
not reported
whether or not
all participants
completed the
study.
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Sanoski, C.
A., Schoen,
M. D.,
Gonzalez, R.
C., Avitall, B.,
& Bauman, J.
L. (1998).

Review the
rationale and
development of a
multidisciplinary
amiodarone clinic
Document the
clinical outcomes
resulting from
implementation of
the amiodarone
clinic.

60 patients
were
enrolled in
the
amiodarone
clinic and
adherence to
monitoring
guidelines
was
compared
before
enrollment
into the
amiodarone
clinic and
after
enrollment.

Retrospective
chart review

29
In a sample of 60
patients,
adherence to
monitoring
guidelines was
compared before
and after
enrollment in the
amiodarone clinic

Before enrollment into
the amiodarone clinic,
23% of the patients
were adherent to
monitoring guidelines.
After enrollment, 90%
were adherent to
monitoring guidelines.
Previously
unrecognized
adverse events were
detected in 35% of
the patients enrolled
into the amiodarone
clinic.

Level IV
Follow-up was
sufficient to
give data for
the
amiodarone
clinic cohort,
the diagnostics
completed
were objective,
and statistical
testing was
used to
compare
adherence to
monitoring
guidelines
before and
after referral to
the
amiodarone
clinic.
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Snider, M.,
Kalbfleisch,
S., & Carnes,
C. A. (2009).

To monitor
antiarrhythmic
drug therapy to
improve the
continuity and
consistency of
care for patients
receiving class I or
class III
antiarrhythmic
drugs.

134 patients
receiving
amiodarone,
sotalol,
dofetilide,
and
propafenone
who were
referred to
an
arrhythmic
medications
clinic in
Columbus,
Ohio
between July
2007 and
April 2008.

Retrospective
chart review

30
Patient's
diagnostic testing
completion before
enrollment was
compared to post
enrollment
adherence to
diagnostic testing
according to
monitoring
protocols.

Pharmacist
monitoring appeared
to improve patient
adherence to
recommended testing
protocols (98.5%
compliance versus
59% before
enrollment in the
clinic).
Pharmacist
monitoring of
outpatient
antiarrhythmic
medication therapy
appeared to help
identify adverse
events and clinically
significant drug
interactions.

Level IV
Inspected the
same group of
patients before
and after
enrollment into
an
antiarrhythmic
monitoring
clinic over a
ten month
period. Data
were analyzed
using the
Fisher exact
test or chi
square testing
to remove bias
and led to valid
study results.
Since the
same group of
participants
comprised the
two cohorts,
demographics
bias was
eliminated.
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Spence, M.
M., Polzin, J.
K.,
Weisberger,
C. L., Martin,
J. P., Rho, J.
P, & Willick,
G. H. (2011).

To assess rates of
lab monitoring of
liver, thyroid, and
pulmonary
function and
adverse events in
a pharmacistmanaged
amiodarone
monitoring
program
compared with
usual care
To estimate the
return on
investment from
this intervention

2292
patients who
received at
least 100
days of
amiodarone
from June 1,
2007 through
May 31,
2009. 181
patients were
in the
intervention
cohort and
2111 were in
the usual
care cohort.

Retrospective
cohort study

31
Those patients in
the intervention
(pharmacistmanaged
program) cohort
and the usual
care cohort were
compared for
adherence to
testing at any time
during the year
after the initiation
of amiodarone

Amiodarone program
- LFT
Baseline - 84%
6 months - 84.5%
1 year - 75.7%
- TFT
Baseline - 70.2%
6 months - 81.8%
1 year - 77.3%
- PFT
Baseline - 6.6%
Within 1 year - 51.9%
Usual care
-LFT
Baseline - 76.3%
6 months - 69.7%
1 year - 61.5%
- TFT
Baseline - 62.7%
6 months - 50.2%
1 year - 46.8%
-PFT
Baseline - 3.6%
within 1 year - 14%
A 200% return
investment was
demonstrated with
the pharmacistmanaged program.

Level IV
Follow-up was
sufficient to
give data for
the
amiodarone
clinic cohort
and a specific
timeline is
discussed.
Objective
diagnostics
removed bias
and statistical
testing was
completed to
compare
demographic
data and
adherence to
baseline as
well as
continued
amiodarone
monitoring.
Randomization
did not occur.
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Critical appraisal of the RCT. Several questions were utilized as identified by Melnyk
and Fineout-Overholt (2011) when critically appraising RCTs. These questions included
assessment of (a) the validity of the study results, (b) the results including intervention/treatment
effect, and (c) the applicability of the results to clinical practice.
Raebel and colleagues (2006) completed a study using an electronic tool to alert
pharmacists to missing laboratory testing of patients on medications requiring routine laboratory
monitoring based on published guidelines established by pharmacists and physicians. The
percentage of patients who completed the laboratory testing was compared between the
intervention and usual care groups using the x2 test. Out of 160 patients in the intervention
group, 114 (71%) completed the recommended testing compared to 161 patients in the usual
care group, 89 (55%) of whom completed the recommended testing (p < .01). The analyses
were completed using SAS software. The electronic tool used to remind pharmacists to order
recommended testing increased the percentage of patients who received laboratory monitoring.
This computerized tool may be a useful addition to an amiodarone clinic as exemplified by the
increased number of patients on amiodarone who received recommended testing.
This RCT represents Level IIa evidence (Raebel et al., 2006). The study results were
valid since (a) the study participants were randomly assigned to the experimental and control
groups, (b) the random assignment was concealed from those enrolling participants into the
study, (c) the participants and providers were blinded to the study group, (d) the study was
completed over a year time period, (e) the participants were analyzed in their respective group,
and (f) the participants in each group were similar based on statistical testing. It was not
reported whether or not all participants completed the study.
Critical appraisal for the cohort studies. The questions identified by Melnyk and
Fineout-Overholt (2011) in the critical appraisal of cohort studies include (a) the validity of the
study results, (b) the results including the strength of association between the exposure and

EFFECTS OF AN APN-LED AMIODARONE CLINIC

33

outcome, and (c) the applicability of the results to clinical practice. These Level IV studies are
discussed below in chronological order of publication date.
Sanoski, Schoen, Gonzalez, Avitall, and Bauman (1998) developed the first documented
multidisciplinary amiodarone monitoring clinic. Sixty patients were referred to the amiodarone
clinic. Comparison was made in adherence to monitoring guidelines before and after enrollment
into the amiodarone clinic. Before enrollment in the amiodarone clinic, only 14 (23%) of the
patients received appropriate monitoring as compared to 54 (90%) after enrollment in the
amiodarone clinic. The authors also reported that previously undiagnosed adverse events were
found in 21 (35%) of the patients enrolled in the amiodarone clinic. The researchers concluded
that a multidisciplinary amiodarone clinic improves patient outcomes by monitoring for early
recognition of medication-related toxicities and modifying medication dosage as indicated.
Participants were evaluated before and after referral to the amiodarone clinic (Sanoski et
al., 1998). Follow-up was sufficient to give data for the amiodarone clinic cohort, although a
specific timeline was not discussed within the report. The diagnostics completed were objective
to remove bias, leading to valid study results. Chi-square testing was used to compare
adherence to monitoring guidelines before and after referral to the amiodarone clinic. Not only
did appropriate monitoring increase, but also the diagnosis of previously unrecognized adverse
effects and amiodarone dose decreased or were discontinued depending on the severity of the
adverse effects.
Graham, Wright, and Manley (2004) hypothesized that an amiodarone management
clinic would improve adherence to published monitoring guidelines. In a retrospective chart
review, the authors compared those patients enrolled in the amiodarone management clinic with
those receiving usual care. Data obtained from the two cohorts (154 patients in the amiodarone
management clinic group and 71 patients in the standard medical care group) were compared
using x2 or Fisher’s exact test. No statistically significant differences were found in baseline
monitoring adherence, but those patients enrolled in the amiodarone clinic were more likely to
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adhere to monitoring guidelines for follow-up thyroid and liver function tests, eye examinations,
and electrocardiograms. The authors also identified those patients taking interacting
medications and compared adverse effects of these medications with amiodarone in both
groups. The only significant finding was those patients taking warfarin were monitored more
closely in the amiodarone management clinic group. It was hoped by the authors that the
amiodarone management clinic would prove to identify adverse effects earlier to allow for
prompter treatment of adverse effects, but differences between the groups did not allow for
significant results. The standard medical care group took amiodarone for an average of one
year where those enrolled in the amiodarone management clinic took amiodarone for an
average of two years.
This study included two groups of participants, one group was evaluated as a “usual
care” group and another group was those enrolled in the amiodarone clinic (Graham et al.,
2004). Follow-up was sufficient to give data for the amiodarone clinic cohort; a specific timeline
of one year post implementation of the amiodarone clinic was discussed. The diagnostics
completed were objective to remove bias, leading to valid study results. Statistical testing was
completed to compare demographic data and adherence to baseline as well as continued
amiodarone monitoring.
Snider, Kalbfleisch, and Carnes (2009) compared compliance of antiarrhythmic
laboratory monitoring before and after enrollment into a pharmacist-led antiarrhythmic
monitoring clinic. In a retrospective chart review, the authors found that 59% of the patients
were compliant with all recommended laboratory and diagnostic testing before enrollment into
the clinic and compliance increased to 98.5% after the initial clinic visit. Amiodarone was
reported to have the highest rate of detected adverse events that were previously unrecognized.
The conclusion was reached that implementation of a pharmacist-led antiarrhythmic monitoring
clinic was associated with an improvement in patient adherence to monitoring guidelines and
earlier recognition of adverse drug events.
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This retrospective chart review inspected the same group of patients before and after
enrollment into an antiarrhythmic monitoring clinic over a ten month period (Snider et al., 2009).
Data were analyzed using the Fisher exact test or x2 testing to remove bias and led to valid
study results. Since the same group of participants comprised the two cohorts, demographics
bias was eliminated.
Johnson, Canty, Billups, and Schimmer (2010) compared those patients receiving usual
care to those patients enrolled in a pharmacist-led amiodarone management service using a
retrospective cohort design. Adherence was defined as completing baseline, six month, and 12
month monitoring per recommended guidelines for liver and thyroid function test as well as
baseline and yearly chest x-rays and electrocardiograms (EKGs). Monitoring adherence rates
between the two groups were compared using x2 testing. The amiodarone monitoring service
group had better adherence rates for liver/thyroid function monitoring and EKG monitoring but
was statistically significant for liver function monitoring and EKG monitoring only. The authors
also identified that the amiodarone monitoring service group had significantly lower adverse
drug events (21 events in the amiodarone monitoring service group as compared to 48 events in
the usual care group).
Two groups of participants were included in the study design (Johnson et al., 2010); one
group was evaluated before the amiodarone clinic was implemented and the other group
included those enrolled in the amiodarone clinic. Follow-up of four years for each group was
sufficient to give data for each cohort. Objective diagnostics removed bias, x2 statistical testing
was completed to compare demographic data and adherence to baseline as well as continued
amiodarone monitoring.
The most recent amiodarone monitoring clinic found in the literature search was a study
conducted by Spence et al. (2011). This study’s objective was to compare rates of laboratory
monitoring of liver, thyroid, and pulmonary function as well as adverse drug events in a
pharmacist-led amiodarone clinic as compared to usual care using a retrospective cohort study
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design. Monitoring rates were compared using x2 tests. Results showed that monitoring rates for
liver and thyroid function at baseline and follow-up were significantly higher in the pharmacistled amiodarone group as well as the obtainment of baseline chest x-rays. It was also shown that
patients in the amiodarone clinic were less likely to be hospitalized for adverse drug events as
compared to the usual care group leading the authors to hypothesize that a positive return on
investment may be experienced from implementation of an amiodarone clinic.
This study also included two groups of participants; one group consisted of those
participants who were seen in the medical centers without the amiodarone clinic and the other
group consisted of those participants who were seen in the medical centers with the
amiodarone clinic (Spence et al., 2011). Follow-up was conducted over a two year period, which
was sufficient to give data for the amiodarone clinic cohort. Objective diagnostics removed bias
and x2 statistical testing was completed to compare demographic data and adherence to
baseline as well as continued amiodarone monitoring. Randomization of participants did not
occur as selection for the groups was based on which medical center participants used.
All of these studies included in the review of literature utilized retrospective chart reviews
of non-randomized subjects leading to a lower level of evidence and bias. Multiple factors
included selection bias, inadequate sample size, and disproportionate cohort sizes.
Nonetheless, the data included did show clinical significance and provided evidence of
improved patient outcomes through implementation of a monitoring clinic for amiodarone.
Critical appraisal for the descriptive study. This study was included as evidence in
order to provide additional literature regarding the inobservance of monitoring guidelines.
Guidelines for critical appraisal of qualitative evidence were used to critically appraise this Level
VI study (Melnyk & Fineout-Overholt, 2011) and included (a) the validity of the study results, (b)
the quality of the description of the findings, and (c) the applicability of the results to clinical
practice. A nonrandomized sample was included in this study; all patients meeting inclusion
criteria were included.
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In 2006, a study was published comparing institutional adherence to recommended
guidelines for the monitoring of amiodarone therapy. Bickford and Spencer (2006) completed a
retrospective chart review for both inpatients and outpatients at a medical university and found
that of the 45 inpatients initiated on chronic amiodarone therapy, only 5 (11%) completed all of
the recommended baseline diagnostic testing. Twenty outpatients were identified on chronic
amiodarone therapy. The number of patients completing all of the recommended baseline
diagnostic testing was not reported. Baseline liver function tests (LFTs) were completed in 95%
of the patients, thyroid function tests (TFTs) were completed in 75% of the patients, chest x-rays
(CXRs) were completed in 75% of the patients, and pulmonary function tests (PFTs) were
completed in 30% of the patients. Only 35% of the patients completed a six month LFT, 20%
completed TFTs, and 50% completed a CXR. The authors hypothesized that adherence to
recommended amiodarone monitoring guidelines might be enhanced through electronic
reminders to order appropriate diagnostic testing, the implementation of amiodarone protocols,
or the implementation of multidisciplinary amiodarone monitoring clinics.
The convenience sample of patients was taken over a five month period to assess
adherence to amiodarone diagnostic monitoring (Bickford & Spencer, 2006). The data review
was limited to files available within the hospital database and did not include outside records.
Descriptive statistics were applied to obtain adherence to monitoring. The results collected were
similar to other studies included in the literature review, indicating a need for dedicated
amiodarone clinics.
Critical appraisal for the clinical practice guideline. The HRS guidelines for
amiodarone monitoring were chosen as the clinical practice guideline this EBP project
(Goldschlager et al., 2007). These guidelines were developed based on evidence-based data
and clinical experience of the writing committee in the care of patients taking amiodarone.
According to Melnyk and Fineout-Overholt (2011), clinical practice guidelines should be
appraised for credibility and applicability/generalizability. It is unknown whether the guidelines
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developers were funded researchers of the reviewed studies for the clinical practice guidelines.
Literature was included in the reference list within one year of publication of the updated clinical
practice guidelines. Levels of evidence of the literature review were not identified within the
guidelines. Amiodarone monitoring guidelines are discussed as well as recommendations for
treatment of adverse events and referral recommendations. This guideline was approved by the
HRS Board of Trustees. These amiodarone monitoring guidelines provide a schedule for
amiodarone monitoring as well as a blueprint for follow-up of patients taking amiodarone,
complete with subjective and objective signs and symptoms of amiodarone adverse effects. The
diagnostic testing recommended for amiodarone monitoring can easily be completed by
providers.
Construct EBP
Literature Synthesis. The literature documents that initiation of an amiodarone clinic
not only increases adherence to monitoring guidelines (Graham et al., 2004; Johnson et al.,
2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011, Tafreshi
et al., 2009) as recommended by the Heart Rhythm Society (Goldschlager et al., 2007), but also
increases early recognition of adverse events (Johnson et al., 2010; Sanoski et al., 1998; Snider
et al., 2009; Tafreshi et al., 2009) (see Table 2.3). The benefit of earlier recognition of adverse
events is the extent of morbidity and mortality due to amiodarone toxicity can be lessened
through dose reduction or discontinuation of amiodarone if needed (Johnson et al., 2010;
Sanoski et al., 1998; Snider et al., 2009).
Description of best practice model recommendation. The amiodarone monitoring
guidelines (see Table 2.4) used in this EBP project were modeled after the guidelines
recommended by the HRS. According to HRS guidelines (Goldschlager et al., 2007), certain
diagnostic testing is recommended before initiation of amiodarone and at certain intervals
throughout amiodarone therapy. Testing includes baseline liver function tests (LFTs), thyroid
function tests (TFTs), pulmonary function tests (PFTs) including DLCO (diffusion capacity for
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carbon monoxide), chest x-ray (CXR), electrocardiogram (EKG), and a thorough eye exam. Not
only do these serve as a baseline data for the patient for comparison in the future, but these
baseline diagnostics also aid in the identification of those at higher risk for development of
adverse effects of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009).
In addition, the clinic was led by an APN to assess the effectiveness of this type of clinic
management for increasing adherence to monitoring guidelines and the reduction in adverse
events. After discussion with the electrophysiologist who assisted with the development of the
monitoring protocol, it was decided International Normalized Ratios (INRs) would be followed
weekly for six weeks after initiation of amiodarone due to amiodarone’s potentiation of warfarin.
All of the participants in the study who were on warfarin in conjunction with amiodarone were
followed in a Coumadin clinic, negating the necessity for the project manager to see the
participants on a weekly basis.
Table 2.4
HRS Recommended Amiodarone Monitoring Protocol
Diagnostic test

When test is completed

Liver function test (AST, ALT)

Baseline and every 6 months

Thyroid function test (TSH, FT4 if indicated)

Baseline and every 6 months

Chest x-ray

Baseline and yearly

Pulmonary function test (with DLCO)

Baseline and as needed for suspicion for
pulmonary toxicity
Baseline and as needed for suspicion of eye
impairments
Baseline and yearly

Eye exam
Electrocardiogram
Digoxin monitoring
Warfarin monitoring

After amiodarone loading and as needed for
signs of digoxin toxicity
Weekly for six weeks then based on results

Note. AST = aspartate transaminase; ALT = alanine transaminase; TSH = thyroid stimulating
hormone; FT4 = free thyroxine; DLCO = diffusing capacity of the lungs for carbon monoxide
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Adherence to monitoring guidelines. A review of the literature showed that those
patients receiving amiodarone are not being monitored as recommended by Heart Rhythm
Society guidelines (Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010;
Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; and Spence et al., 2011).
Implementation of specialized clinics dedicated to the monitoring of amiodarone at appropriate
intervals has been shown to increase compliance to guidelines (Graham et al., 2004; Johnson
et al., 2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et al., 2009; and Spence et al.,
2011) as well as increase earlier recognition of adverse events otherwise unnoticed (Snider et
al., 2009; Sanoski et al., 1998; and Spence et al, 2011).
Application of the APN role. Certain limitations have been identified in previous studies
that would be inapplicable in the APN-led clinic. The limitations identified were found in the
pharmacist-led amiodarone clinics and pertained to the ordering of EKGs and CXRs.
Pharmacists are limited to the ordering of laboratory tests only and relied upon the patient’s
primary physician to order the other diagnostics needed for monitoring guidelines (Johnson et
al., 2010; Spence et al., 2011). In Indiana, an APN has the ability to order not only the
laboratory diagnostics, but also other diagnostics such as EKGs, CXRs, and PFTs (Phillips,
2005). Thus, the use of an APN-led clinic would resolve the issue of ordering diagnostic testing
found in pharmacist-led amiodarone clinics. Naylor and Kurtzman (2010) discussed the use of
nurse practitioners in delivering high quality care. They found that the care provided was
comparable with care delivered by physicians and in some instances, better with regards to
patient follow-up; patient satisfaction; and more improved screening, assessment, and
counseling (Naylor & Kurtzman, 2010), qualities which provide for a successful amiodarone
monitoring clinic.
Answering the clinical question. The clinical question put forth in this EBP project was
constructed using the PICOT format outlined by Melnyk and Fineout-Overholt (2011). The
clinical question addressed by this EBP project was: What effects will an APN-led outpatient
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amiodarone clinic have on adherence to amiodarone monitoring guidelines in the adult
population over four months? In order to answer this clinical question, a practice change was
implemented within a cardiology practice which encompassed an amiodarone clinic managed
by an APN using HRS guidelines (Goldschlager et al., 2007). A comparison of adherence to
amiodarone monitoring guidelines was completed using a chart review of two cohorts, one
before initiation of an amiodarone clinic, and one after the practice change of implementation of
an amiodarone clinic.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
Participants and Setting
A northern Indiana cardiology practice was chosen as the site for the implementation of
the evidence-based practice (EBP) project. The purpose of this project was to compare patient
adherence to recommended HRS monitoring guidelines for amiodarone (Goldschlager et al.,
2007). This practice serves two different sites in the area with monthly patient volumes of
around 100 patients. Participants included a convenience sample of patients newly initiated on
amiodarone therapy during a consultation with the electrophysiologist at either site during the
EBP project. Information was gathered from a chart review completed by the EBP project
manager after initiation of the APN-led clinic and was compared to data collected from a chart
review of participants receiving amiodarone during the previous year.
Before beginning the EBP project, neither site had a drug-monitoring program. The
cardiology staff would initiate recommended diagnostic testing prior to amiodarone initiation as
well as maintenance diagnostic testing. According to HRS guidelines, maintenance diagnostic
testing consisting of LFTs and TFTs should occur at least every six months and a CXR should
be performed at least yearly in all patients taking amiodarone (Goldschlager et al., 2007). Often
times, a stable patient may only be seen by this cardiology practice every one to two years,
increasing the likelihood that adherence to monitoring guidelines would be lost.
Outcomes
The primary outcome of this EBP project was a comparison to adherence to
recommended HRS monitoring guidelines of amiodarone before and after implementation of an
amiodarone clinic in an effort to identify adverse drug events and decrease negative outcomes
(Goldschlager et al., 2007). A chart review of patients participating in the amiodarone clinic was
compared to a chart review of patients seen in the cardiology clinic in 2012. A secondary
outcome was to identify decreased morbidity and mortality associated with amiodarone use due
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to the projected increased of adherence to monitoring guidelines and early recognition of
adverse effects after participation in the amiodarone clinic.
Planning
The foundation for the evidence-based practice project started with a discussion of the
proposed amiodarone clinic with the electrophysiologist of the practice and the practice
manager. Both welcomed the idea of the proposed amiodarone clinic as an enhancement of
patient care. Collaboration with the electrophysiologist took place to construct a patient teaching
information sheet (see Appendix A), establish a protocol for initial and maintenance amiodarone
monitoring based on HRS guidelines (see Table 2.4), and develop a standard
subjective/objective assessment protocol (see Appendix B) for use in the amiodarone clinic
(Goldschlager et al., 2007). After discussion with the EBP academic advisor, it was decided that
a chart review would be more appropriate for the project and the amiodarone clinic would be
initiated by the cardiology practice staff.
Intervention
Participants in the amiodarone clinic completed initial diagnostic testing based on HRS
guidelines at the time of amiodarone initiation (Goldschlager et al., 2007). Baseline testing
consisted of LFTs and TFTs as well as a chest x-ray that were often times completed the day of
consultation. The participant was then scheduled for a PFT at the participant’s earliest possible
convenience. A follow-up visit was scheduled with the cardiology staff shortly after completion of
the diagnostic testing to discuss the results of the initial diagnostic testing, perform further
participant teaching regarding the use of amiodarone and its potential adverse effects, evaluate
for compliance of amiodarone loading if applicable and ensure maintenance dose was started,
and answer any questions the participant may have regarding amiodarone use and side effects.
More intensive monitoring of known medication interactions was discussed with the participant if
needed. Based on HRS guidelines, weekly monitoring of INRs for the first 4-6 weeks post
amiodarone initiation is recommended to assess for interactions between amiodarone and
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warfarin and allow for warfarin dose modification (Goldschlager et al., 2007). HRS guidelines
also recommend more frequent digoxin levels during the concomitant use of amiodarone and
digoxin (Goldschlager et al., 2007). Another visit was scheduled one month after the initial visit
with the cardiology staff to evaluate the participant for adverse effects and evaluate for
compliance of amiodarone therapy and adherence to monitoring guidelines. Participants were
encouraged to call as needed for suspicion of adverse effects of amiodarone for cardiology
evaluation.
Recruitment
Data for the EBP project were collected by a retrospective chart reviews. Participants in
the cardiology practice’s amiodarone clinic were compared to those participants seen by the
cardiology practice in 2012 on amiodarone. Inclusion criteria included those participants over 18
years of age newly initiated on amiodarone during the specified time period. Exclusion criteria
included participants under the age of 18 and those not on amiodarone.
Data
Measures and their reliability and validity. Lack of any previous formal drug
monitoring program identified the necessity of the evidence-based practice project. Literature
found in the first three steps of the ACE Star model supported the need for the amiodarone
clinic to enhance adherence to monitoring guidelines for the use of amiodarone. In the first
stage of discovery of research, it was recognized that patients on amiodarone therapy have
adverse effects not recognized in a timely manner and new ways to improve recognition were
identified through the use of an amiodarone clinic protocol. The second stage of evidence
summary showed the use of outpatient amiodarone clinics improved the discovery of the
adverse effects of amiodarone through adherence to monitoring guidelines. Translation to
Guidelines in the third step utilized HRS guidelines for amiodarone monitoring through the use
of amiodarone clinics to evaluate patients for early signs of adverse effects of amiodarone
(Goldschlager et al., 2007).
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A data collection tool (see Appendix C) was developed to collect demographic data
including age, height, weight, gender, and race as well as length of amiodarone use, concurrent
use of warfarin or digoxin, and a current medication list. This information was used to compare
the two cohorts during the chart review to assess for bias in the data collected. Statistical
comparisons were made between the groups in order to increase the reliability that the
adherence to monitoring results was due to the amiodarone clinic. Consistency of data
collection was maintained by the use of the same data collection tool for each participant with
the same person collecting and recording the data. Validity was maintained by the use of data
measures from the electronic medical record.
Collection. A variety of data were collected during this project. A demographic sheet
was completed by the project manager consisting of the participant’s age, height, weight,
gender, race, current medical problems, and current medication list. At the bottom of the
demographic sheet was a flow sheet to record completion of diagnostic testing. This data
collection sheet was used both for the usual care cohort as well as the amiodarone clinic cohort.
Data were coded using a code key (see Appendix D) that was secured in a locked cabinet
separately from the data collection sheets to maintain confidentiality of the participants.
Management and analysis. Adherence to guidelines at the initiation of the amiodarone
clinic was compared to those not enrolled in the amiodarone clinic. The data for those
participants not enrolled in the amiodarone clinic were obtained from a retrospective chart
review of the participants on amiodarone in the previous year at the cardiology practice where
the project took place. Independent t-tests were used to compare age, weight, and height of the
participants and x2 tests were used to compare adherence to guidelines between the
participants enrolled in the amiodarone clinic and those not enrolled in the amiodarone clinic as
well as participant gender, use of warfarin, and use of digoxin.
The data collection tool created for use during this EBP project was based on data
collected in other comparisons of amiodarone clinics included in this EBP project report
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Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009). The data
collected were used to compare the two groups included in this EBP project using SPSS
software.
Protection of Human Subjects
Several methods were employed to protect the participants and their rights during the
evidence-based practice project. In the early stages of the project, the project manager
completed training through the National Institute of Health geared towards the protection of
human subjects. Institutional Review Board approval through Valparaiso University was
obtained as well as approval through the cardiology practice facility. All data were coded and
the code key and data were kept separately in a locked cabinet accessible only by the project
manager.
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to evaluate if the implementation of a nurse-led
amiodarone clinic would increase monitoring according to HRS-recommended monitoring
guidelines. The question was answered using descriptive statistics to analyze data collected
prior to the implementation of the amiodarone clinic and after through retrospective chart
reviews. Statistical and descriptive analyses of the data collected before and after initiation of
the amiodarone clinic were performed to answer the clinical question. Implications regarding the
results identified will be discussed at more length in Chapter 5.
Participant Characteristics
Data for the baseline cohort were obtained through a retrospective chart review of all
patients seen in the electrophysiology clinic in the year 2012. A total of ten participants (seven
males and three females) were identified and included in this baseline cohort. The amiodarone
clinic was initiated at the cardiology clinic in August of 2013. Nine participants (seven males and
three females) were identified in the amiodarone clinic cohort for inclusion. Data abstracted from
the charts included demographic data consisting of age, height, weight, gender, and race, along
with date of amiodarone initiation, length of amiodarone use, use of warfarin, use of digoxin,
medical history, and a current medication list.
Demographic data (see Tables 4.1 and 4.2) consisting of age, height, weight, race, and
gender was compared between the two cohorts. An independent samples t test that compared
the mean height, weight, and age of the two cohorts was conducted (see Table 4.3). No
significant difference was found between the two groups in age (t(17) = -.03, p = .97), height
(t(17) = -1.57, p = .13), and weight (t(17) = .82, p = .43). A chi-square test of independence was
calculated comparing the race and gender between the two groups. No significant difference
was found for race (X2(1) = 2.01, p = .16) or gender (X2(1) = 3.21, p = .07).
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Table 4.1
Group Statistics for Demographics (age, height, weight)
Pre-amio clinic
Post-amio clinic
(n = 10)
(n = 9)
M (SD)
Age (in years)

74.50 (10.63)

74.67 (10.97)

Height (in inches)

69.40 (2.41)

71.22 (2.64)

215.50 (56.42)

195.22 (51.14)

Weight (in pounds)

Table 4.2
Group Statistics for Demographics (race, gender)
Race
Caucasian African-American
Pre-Amio Clinic
n (percentage)
Post-Amio Clinic
n (percentage)

Gender
Male

Female

8 (80%)

2 (20%)

7 (70%)

3 (30%)

9 (100%)

0 (0%)

9 (100%)

0 (0%)

Table 4.3
Independent Samples Test for Demographics (age, height, weight)
Levene's Test
for Equality of
Variances
F
Age
Height
Weight

.05
.06
.27

t-test for Equality of Means

Sig.
.84
.81
.61

Changes in Outcomes

t
df
-.03 17
-1.57 17
.82 17

Sig.
95% CI
(2Mean
Std. Error
Lower Upper
tailed) Difference Difference
.97
-.17
4.96
-10.62 10.29
.13
-1.82
1.16
-4.27
.62
.43
20.28
24.81
-32.07 72.62

EFFECTS OF AN APN-LED AMIODARONE CLINIC

49

Prior to the initiation of the amiodarone clinic, it was found that adherence to HRS
monitoring guidelines needed improvement. All nine participants included in the amiodarone
cohort completed the educational session. In the pre-amiodarone clinic cohort (n = 10), baseline
diagnostic monitoring adherence for EKG, TFT, LFT, CXR, and PFT were at 60%, 40%, 30%,
50%, and 10% respectively (see Table 4.4). After initiation of the amiodarone clinic (n = 9), the
percentage of adherence increased to 100%, 66.7%, 66.7%, 88.9%, and 33.3% respectively
(see Table 4.4). Adherence to the baseline eye exam was at 0% for the pre-amiodarone clinic
cohort and did not change after initiation of the amiodarone clinic.
Table 4.4
Adherence to Baseline Monitoring Pre and Post Amiodarone Clinic

Diagnostics
EKG
TFT
LFT
CXR
PFT
Eye Exam

Number Completed
Pre-Amio Clinic
Post-Amio Clinic
(n = 10)
(n = 9)
6 (60%)
9 (100%)
4 (40%)
6 (66.7%)
3 (30%)
6 (66.7%)
5 (50%)
8 (88.9%)
1 (10%)
3 (33.3%)
0
0

Statistical testing. Participants in the pre-amiodarone clinic cohort were compared to
the post-amiodarone clinic cohort with respect to adherence to HRS monitoring guidelines for
baseline diagnostics (see Table 4.4). When the two groups were compared using the chi-square
of independence for baseline diagnostics, a significant difference was found in the postamiodarone group for baseline EKG (X2 (1) = 4.56, p = .03). Although the results were not
significantly different, baseline TFT (X2 (1) = 1.35, p = .25), baseline LFT, (X2 (1) = 2.55, p =
.11), CXR (X2 (1) = 3.32, p = .07), and PFT (X2 (1) = 1.55, p = .21) diagnostics all improved;
those participants in the post-amiodarone clinic group were more likely to complete the
recommended diagnostics.
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Significance. Based on the data collected and analyzed for this EBP project, a nurseled amiodarone clinic increased adherence to amiodarone monitoring using HRS guidelines
(see Figure 4.1). Although not all the results were statistically significant, adherence to
amiodarone monitoring increased in all diagnostic studies except for eye exams after the
amiodarone clinic was implemented. Seven (77.8%) of the nine amiodarone clinic participants
remained on amiodarone during the EBP project.
Figure 4.1
Percent Adherence to Monitoring Pre-Post Amiodarone Clinic
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Drug interactions. Out of the nine participants in the amiodarone clinic, six (66.7%) of
them were concurrently taking warfarin. All six of these patients were followed through a
Coumadin clinic not part of the amiodarone clinic. Each respective Coumadin clinic was alerted
to patient initiation of amiodarone and weekly INRs were completed on all six patients for six
weeks and then weekly until two consecutive INRs were within range per the Coumadin clinic
protocol. None of the participants in the amiodarone clinic were concurrently taking digoxin.
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Past medical history. All nine (100%) of the participants in the amiodarone clinic were
prescribed amiodarone for the treatment of atrial-based arrhythmias. Three (33.3%) of the
participants had concurrent coronary artery disease. Four (44.4%) of the participants had
concurrent hyperlipidemia, receiving statin therapy and/or fenofibrate therapy.
Amiodarone morbidity. Two (22.2%) of the participants in the amiodarone clinic had
their amiodarone discontinued during this EBP project. One of the patients was admitted for
pneumonia towards the end of the EBP project which led to the immediate withholding of
amiodarone until further diagnostics could be completed. A CT scan showed fibrotic changes
consistent with early amiodarone pulmonary toxicity. The other participant had persistent
nausea, dizziness, and insomnia after two months on amiodarone. No signs of liver, thyroid, or
eye effects from amiodarone were observed on either participant during the EBP project.
Amiodarone mortality. None of the participants died during the EBP project due to
amiodarone adverse effects or otherwise.
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CHAPTER 5
DISCUSSION
The purpose of this EBP project was to observe the effects of an APN-led amiodarone
clinic on adherence to monitoring per HRS guidelines (Goldschlager et al., 2007). Based on
other research findings in the literature, use of an amiodarone clinic increased adherence to
monitoring (Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009;
Spence et al., 2011). This EBP project supported those recommendations as adherence to
amiodarone monitoring increased after enrollment into the amiodarone clinic.
Explanation of Findings
Data for this project were collected using a retrospective chart review pre and post
amiodarone clinic. Demographic data were collected from each group and compared for
significant differences between the two groups which would impact the validity of the findings.
Baseline monitoring data including baseline EKG, TFT, LFT, CXR, and PFT were collected and
compared in the pre and post amiodarone participants. Monitoring data were analyzed using
SPSS software. An independent samples t-test was used to compare age, height, and weight of
the participants in the pre and post amiodarone clinic participants. Chi-square testing was used
to evaluate for significant differences in gender and race in the pre and post amiodarone clinic
participants as well as the appraisal of adherence to diagnostic monitoring between the pre and
post amiodarone clinic participants.
Answer to PICOT question. The original PICOT question was: Does enrollment in an
amiodarone clinic compared with “usual care” change adherence to monitoring as
recommended by best practice guidelines and allow for earlier recognition of adverse effects of
amiodarone to decrease negative patient outcomes over a four month time period? Adherence
to monitoring for baseline EKGs, TFTs, LFTs, CXRs, and PFTs increased over the four month
period in the APN-led amiodarone clinic. Two patients were found to have significant adverse
effects from amiodarone prompting discontinuation of amiodarone. Both of these patients
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recovered after the early recognition of amiodarone adverse effects and discontinuation of
amiodarone.
Pre-amiodarone clinic diagnostic adherence. Of the ten participants identified prior to
the implementation of the amiodarone clinic, baseline EKG completion was 60%, baseline TFT
completion was 40%, baseline LFT completion was 30%, baseline CXR completion was 50%,
and baseline PFT completion was 10%. A review of the literature included studies evaluating
adherence to baseline amiodarone monitoring in the absence of a dedicated amiodarone clinic
(Bickford & Spencer, 2006; Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998;
Snider et al., 2009; Spence et al., 2011; Stelfox et al., 2004). The EBP project results found in
the retrospective chart review of participants not enrolled in the amiodarone clinic were similar
to the results in the literature. Bickford and Spencer (2006) reported higher baseline TFT, LFT,
CXR, and PFT results (82%, 87%, 87%, and 24% respectively). Stelfox and colleagues (2004)
reported baseline adherence rates for LFT (42%), TFT (40%), and CXR (50%) which were
similar to the baseline adherence rates in the pre-amiodarone clinic participants in the EBP
project.
Post-amiodarone clinic diagnostic adherence. After implementation of the
amiodarone clinic, baseline completion of EKG diagnostics rose from 60% to 100% and was
statistically significant. When comparing the findings from this EBP project to the literature,
mixed results were found. In a study by Graham and colleagues (2004), EKG adherence was
not shown to be significantly improved (41% in the amiodarone clinic cohort as compared to
32% in the usual care cohort). In other studies, adherence to EKG monitoring in this EBP
project was similar to those results reported in the literature post implementation of an
amiodarone clinic (Graham et al., 2004; Johnson et al., 2010; Sanoski et al., 1998; Snider et al.,
2009; Spence et al., 2011). Snider and associates (2009) described increased adherence to
amiodarone monitoring for baseline EKG adherence (from 80% to 100%).
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Post amiodarone monitoring in this EBP project for TFT (66.7%) and LFT (66.7%)
increased. In 2004, Graham and colleagues reported improved adherence for continued
amiodarone monitoring for TFT (66%) and LFT (69%) in the amiodarone clinic cohort as
compared to the usual care group with adherence rates of 37% for TFT and 38% for LFT.
Johnson and colleagues (2010) found that baseline adherence rates increased for LFT (from
44% to 69%) and TFT (from 49% to 55%) after implementation of an amiodarone clinic.
Spence and associates (2011) found that PFT adherence rates rose from 3.6% to 6.6%
after implementation of an amiodarone clinic. In this EBP project, similar baseline PFT results
were document prior to the implementation of the amiodarone clinic (10%), but rose to 33.3%
after implementation of the amiodarone clinic. Snider and colleagues (2009) reported
improvement in baseline PFT adherence from 30% to 100% after initiation of an antiarrhythmic
medications clinic.
In this EBP project, baseline CXR adherence increased post amiodarone clinic.
However, in the literature, mixed results for baseline CXR adherence were reported. Snider and
associates (2009) described increased adherence to amiodarone monitoring for CXR (from 70%
to 100%) after implementation of antiarrhythmic medications clinic. Spence and colleagues
(2011) revealed an increase for baseline CXR (from 49.3% to 59.1%) after initiation of an
amiodarone clinic. Johnson and associates (2010) found that baseline adherence for CXR was
reported as better in the usual care cohort (56%) as compared to those enrolled in the
amiodarone clinic (45%).
The amiodarone clinic for this EBP project did not improve adherence to baseline eye
exam completion. Only one study included in the literature review discussed baseline
adherence to eye exams (Graham et al., 2004). In their study, baseline adherence to eye exams
increased from 15% to 30% after implementation of an amiodarone clinic.
Post-amiodarone adverse events. Various amiodarone adverse events were
documented in the literature. In this EBP project, 2 adverse events (22.2%) were documented.
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One participant had evidence of early pulmonary toxicity and the other participant had
musculoskeletal and gastrointestinal adverse effects that impacted activities of daily living.
Adverse events were also reported in the literature. Spence and associates (2011) documented
liver, thyroid, musculoskeletal, and pulmonary reactions to amiodarone as well as digoxin
toxicity with concurrent amiodarone administration. When compared with the usual care group,
the number of patients affected by adverse events was much less (8 reported adverse events in
the amiodarone clinic group versus 81 in the usual care group). Johnson and researchers
(2010) described fewer adverse events in the amiodarone clinic cohort (21 as opposed to 48 in
the usual care cohort) with the top reported adverse event being thyroid-related. Sanoski and
colleagues (1998) reported adverse effects of amiodarone in 21 (35%) of the 60 patients
enrolled in the amiodarone clinic with the top reported adverse effect being hypothyroidism.
Graham and associates (2004) also found similar adverse effects of amiodarone (the most
common reported were TSH elevation and cough/dyspnea) with more adverse effects
documented in the amiodarone clinic group.
Evaluation of the Applicability of the Theoretical and EBP Framework
Two frameworks led the development, implementation, and analysis of this EBP project:
King’s Theory of Goal Attainment as the nursing model and the ACE Star Model as the EBP
framework.
King’s Theory of Goal Attainment. King’s Theory of Goal Attainment (King, 1971;
King, 1981) functioned as the theoretical framework for this EBP project. Goal attainment was
modified to describe the relationship between the project manager and the participants in the
amiodarone clinic.
Concepts related to the project manager. In the Theory of Goal Attainment, nursing is
responsible for assessing patients’ needs to improve health, developing a trusting, therapeutic
relationship with patients, and guiding patients to achievement of a mutual goal to improve
health (King, 1971; King, 1981). In this case, it was the project manager’s responsibility to
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develop a treatment plan with the input of the amiodarone clinic participant. It was important to
incorporate individualized stressors and barriers to goal attainment as well as deliver the
education necessary to allow the amiodarone clinic participant to fully take part in the plan of
care related to goal attainment.
Concepts related to the participants in the amiodarone clinic. The participants in the
amiodarone clinic made up the interpersonal system that is the heart of King’s Theory of Goal
Attainment. The interpersonal system is made up of three parts: the personal system (the
participant in the amiodarone clinic), the interpersonal system (the interaction between the
project manager and the participant in the amiodarone clinic), and the social system (those
individuals whom the participants chose to bring with them to follow-up appointments in the
amiodarone clinic) (King, 1971; King, 1981). These individuals in the social system included
family, friends, or caregivers.
Even though goals were mutually set, the amiodarone clinic participant was still
responsible for completion of the recommended diagnostic monitoring. It was found after
discussion with the participants that EKGs were easy to complete due to the fact that they were
completed at the follow-up appointments with the project manager. Lab diagnostics and CXR
were also similarly easy to complete as they could be done immediately after the appointments.
PFTs and eye exams were the most difficult to complete as reported by the amiodarone clinic
participants as these had to be scheduled at a later date and at another facility. Further
education could be done stressing the importance of the necessity for baseline PFTs and eye
exams. This way a more thorough discussion could be had with the patient in order to fully
attain the mutual goal of completion of all baseline diagnostics upon the initiation of amiodarone.
Concepts shared by the project manager and the participants in the amiodarone
clinic. The interactions that took place between the project manager and participants in the
amiodarone clinic facilitated the mutual attainment of goals; in this case, improved adherence to
amiodarone monitoring guidelines. These interactions included the initial educational session
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with the participants. The project manager was sure to discuss any potential barriers to
adherence of monitoring guidelines and any stressors that might be involved in scheduling the
diagnostics required outside of the clinic. Barriers and stressors to completion of diagnostic
testing could include financial complications, transportation complications, or simply lack of
wanting to have the diagnostics completed. Some stressors were medication specific and
related to drug-drug interactions between amiodarone and other medications the participants
were taking. The drug-drug interactions included in this EBP project included warfarin and
digoxin. None of the participants included in the EBP project were concurrently taking digoxin,
but six of the nine participants included were taking warfarin. These participants were followed
in a Coumadin clinic and teaching was done with the staff of the Coumadin clinics. Teaching
included amiodarone’s interaction with warfarin, the recommended dosage reduction by onethird to half when starting amiodarone, and weekly INRs for six weeks with dosage adjustments
necessary to maintain therapeutic ranges, then per routine monitoring (Dulak, 2005;
Goldschlager et al., 2007; Siddoway, 2003).
The implementation of the amiodarone clinic was well-received by the cardiology
practice as well as the amiodarone clinic participants. In fact, the participants in the amiodarone
clinic shared how pleased they were with the education delivered by the project manager and
the close follow-up to monitor for adverse effects of amiodarone.
ACE Star Model. The ACE Star Model yielded a five step process to guide this EBP
project (Stevens, 2004). The steps include knowledge discovery, evidence summary,
translation, integration, and evaluation.
Stage 1: Discovery of research. In this stage, original knowledge is exposed through
research and scientific inquiry (Stevens, 2004). In this EBP project, several studies were
identified through a review of literature documenting the success of amiodarone clinics to
improve adherence to monitoring guidelines (Graham et al., 2004; Johnson et al., 2010; Raebel
et al., 2006; Sanoski et al., 1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009).
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By using discovery of research, knowledge regarding the usefulness of amiodarone clinics in
adherence to monitoring guidelines was obtained.
Stage 2: Evidence summary. In this stage, the mass of research is combined into a
single, significant statement, often in the form of systematic reviews, as well as the recurrent
update of knowledge with new evidence (Stevens, 2004). Within the current evidence, the use
of outpatient amiodarone clinics has shown improvement in adherence to monitoring guidelines
(Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski et al., 1998; Snider et
al., 2009; Spence et al., 2011; Tafreshi et al, 2009) and the earlier discovery of adverse effects
of amiodarone (Johnson et al., 2010; Sanoski et al., 1998; Snider et al., 2009; Tafreshi et al.,
2009). A review of the literature did not reveal an APN-led amiodarone clinic, but other APN-led
clinics for chronic disease/medication management were successful (Alfakih et al., 2009; Aziz et
al., 2011; Chandler, 2007; Grange, 2005; Hatchett, 2005; Levine et al., 2012). Success was
documented by patient-reported symptom relief, facilitation of interdisciplinary referrals,
improved patient outcomes, fewer hospital readmissions, and better patient education regarding
chronic condition management (Grange, 2005; Hatchett, 2005; McAfee, 2012). This evidence of
APN-led clinics for other diseases and medication management were used to support the APNled clinic in the EBP project.
Stage 3: Translation to guidelines. Translation allows for evidence delivery into a
summary of useful, relevant information into clinical practice guidelines, care standards, clinical
pathways, organizational protocols, or organizational algorithms through evidence-based
practices and clinical expertise across many patient populations and settings (Stevens, 2004).
Many large healthcare organizations (Johnson et al., 2010; Raebel et al., 2006; Snider et al.,
2009; Spence et al, 2011) have instituted outpatient drug monitoring programs to increase
adherence to monitoring guidelines and increase the identification of adverse drug effects. By
having a monitoring program dedicated to amiodarone monitoring by HRS guidelines, the
confusion regarding who was responsible for monitoring these patients was negated and
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allowed for the early identification of adverse drug effects requiring dose adjustments or
possibly discontinuation of amiodarone (Goldschlager et al., 2007). Multidisciplinary amiodarone
clinics as well as pharmacist-led clinics have been documented in the literature. This EBP
project was the first documented APN-led amiodarone clinic in the literature, and as described,
the APN-led clinic had the potential to offer additional benefits not found in pharmacist-led
amiodarone clinics including the ability to order all of the diagnostic testing recommended by
guidelines including PFTs and CXRs which the pharmacist is not able to do as defined by
pharmacist scope of practice without a collaborating physician (Johnson et al., 2010; Spence et
al., 2011).
Stage 4: Practice integration. Society expects healthcare professionals to remain upto-date on current best practices. In order to complete this task, healthcare professionals and
organizations must be willing to accept new guidelines for practice if the evidence is supportive
of the change (Stevens, 2004).
This EBP project utilized HRS guidelines for the monitoring of amiodarone in a dedicated
amiodarone clinic (Goldschlager et al., 2007). Baseline monitoring was compared between a
chart review of patients prior to initiation of an amiodarone clinic in a small northwestern Indiana
cardiology practice and then another chart review of patients after implementation of an
amiodarone clinic.
Stage 5: Evaluation. Evaluation is the final step in the ACE Star Model and consists of
influences of evidence-based practice on patient outcomes, healthcare professional/patient
satisfaction, efficacy/efficiency of care, economic analysis, and health status (Stevens, 2004).
For this EPB project, outcomes evaluated included the number of participants that completed
baseline diagnostic monitoring before and after initiation of an amiodarone clinic. Previous
studies and reviews suggested an increase in the adherence to monitoring guidelines with the
implementation of an amiodarone clinic and the early identification of adverse effects of
amiodarone allow for early treatment to reduce morbidity and mortality from the use of
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amiodarone (Graham et al., 2004; Johnson et al., 2010; Raebel et al., 2006; Sanoski et al.,
1998; Snider et al., 2009; Spence et al., 2011; Tafreshi et al., 2009).
This EBP project demonstrated that the implementation of an APN-led amiodarone clinic
increased adherence to monitoring guidelines. Furthermore, participants in the amiodarone
clinic expressed increased satisfaction with the enhanced educational process and more
frequent office visits to monitor for adverse effects of amiodarone. Two participants in the
amiodarone clinic were found to have significant enough adverse effects of amiodarone to
warrant discontinuation of amiodarone therapy, further adding to the usefulness of a dedicated
amiodarone clinic and potential improved health status. An APN-led clinic would be more costeffective than a physician-led amiodarone clinic due to the differences in salary requirements.
Additionally, an APN-led clinic can overcome some of the ordering difficulties associated with
the pharmacist-led amiodarone clinics. Pharmacist-led clinics are not able to order certain
diagnostics such as PFTs, CXRs, and EKGs.
Strengths and Limitations of the EBP Project
Strengths. There were several strengths to this EBP project. First, the data collected
supports the use of a dedicated amiodarone clinic to increase adherence to amiodarone per
recommended guidelines. This additional data contributes to the current evidence of the
usefulness of amiodarone clinics in improving adherence to amiodarone monitoring guidelines
and also adds the new knowledge of an APN-led amiodarone clinic. Second was the utilization
of APN skills. APNs can provide valuable care through clinical skills that offer symptom relief,
facilitation of interdisciplinary referrals (McAfee, 2012), as well as provide improved outcomes
for patients as demonstrated by fewer hospital readmissions (Grange, 2005). These tasks are
completed by the APN through education of patients regarding their chronic conditions (Grange,
2005; McAfee, 2012), by more frequent office visits in the amiodarone clinic for earlier
recognition of adverse effects, and by increased compliance with baseline diagnostic testing.
Participants with adverse effects requiring treatment from a specialist (such as those
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experiencing signs and symptoms of hypothyroidism) would be sent to an appropriate
healthcare provider for treatment.
One of the ten participants in the usual care cohort required the discontinuation of
amiodarone due to suspected pulmonary toxicity requiring hospitalization and aggressive
treatment. Two of the nine participants in the amiodarone cohort required the discontinuation of
amiodarone due to adverse effects. One of the two participants was hospitalized for pneumonia
and a CT scan showed fibrotic areas in the lungs suspicious for amiodarone-induced pulmonary
toxicity. The participant was treated and released after a few days and fully recovered. The
other participant experienced GI symptoms and muscle tremors which have since resolved
since stopping amiodarone due to early recognition of adverse effects.
Naylor and Kurtzman (2010) found that the care provided by APNs was comparable with
care delivered by physicians and, in some instances, better with regards to patient follow-up;
patient satisfaction; and more improved screening, assessment, and counseling, qualities which
provide for a successful amiodarone monitoring clinic. Third, patients in this EBP project
expressed their satisfaction with the involvement in and individualization of the treatment plan
as guided by the Theory of Goal Attainment which added to patient accountability for treatment
compliance.
Limitations. This EBP project only drew participants in a non-randomized fashion from
one of the physicians within the cardiology practice over a short period of time. Also, only new
patients to amiodarone were included in the project. Had the time been extended to one year
and participants gathered from all four physicians, the number of participants would have been
larger and more information regarding adherence to amiodarone monitoring per recommended
guidelines in chronic users of amiodarone could have been compared before and after
implementation of the amiodarone clinic. Due to the use of electronic medical records, only
results found in the electronic medical record were included in this EBP project.
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Improvements to adherence could have been made by using reminder letters if baseline
diagnostic testing results were not received within one week of amiodarone initiation. Also, an
alert embedded in the electronic medical record prompting the prescriber of amiodarone to
assess and order baseline diagnostics as required upon initiation of amiodarone could have
improved adherence.
Implications for the Future
Practice (APN role or professional nurse). In the state of Indiana, nurse practitioners
are able to assess patients, order appropriate diagnostic testing, review the diagnostic testing,
and make recommendations to the treatment plan based on diagnostic testing results. These
are all skills needed in the implementation of an amiodarone clinic and negate some of the
limitations found in pharmacist-managed amiodarone clinics. The usefulness of the APN in this
type of role could be expanded to incorporate a multitude of medications that require diagnostic
monitoring, leading to a new niche in healthcare for the APN. An example of another APN-led
clinic may include an arrhythmia clinic dedicated to the monitoring of antiarrhythmic medications
including amiodarone, sotalol, dofetilide, flecainide, and propafenone. In this role, the APN could
provide the patient medication education including uses, side effects, adverse effects,
monitoring protocols; ordering and monitoring of diagnostic testing related to each specific
antiarrhythmic medication; assessment of adverse effects of the antiarrhythmic medication;
dose titration as necessary; and referral as needed to other specialty healthcare providers for
treatment of adverse effects.
Theory. King’s Theory of Goal Attainment was a useful theory in the guidance of the
implementation of the amiodarone clinic due to the incorporation of the patient in the treatment
plan. Adherence to recommended amiodarone monitoring guidelines was improved through
goal attainment by leading the EBP project manager and participants through a series of
transactions to facilitate the decision on a mutual goal while taking into account each
participant’s unique barriers and stressors to goal attainment. Application of the Theory of Goal
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Attainment would be suitable in future research requiring common goal attainment between
researchers and research participants.
Research. An APN-led amiodarone clinic research study could not be found in the
literature. Instead, other APN-led clinics were included in the literature review and applied to
implementation of an amiodarone clinic. Hospital readmission rates decreased after enrollment
into a nurse-led asthma clinic (Chandler, 2005); nurse-led heart failure clinics have
demonstrated an improved quality of life, individualized care, and appropriate medication
management (Grange, 2005); and nurse-led anticoagulation clinics were more cost effective
and found that fewer patients in the nurse-led clinic required hospitalization (Aziz et al., 2011).
This EBP projects starts to fill the knowledge gap found in this area and new research is needed
regarding effects on amiodarone monitoring adherence, patient outcomes, and cost
effectiveness of an APN-led amiodarone clinic to continue to fill the knowledge gap discovered.
Research designs should include longitudinal designs to track the same groups of patients
before and after enrollment into an APN-led amiodarone clinic while incorporating a cost
analysis.
Education. Further education is necessary regarding the lack of adherence to
amiodarone monitoring guidelines and the improved adherence to monitoring guidelines through
the implementation of an amiodarone clinic. This EBP project provides useful information to
cardiology and primary care nurses regarding lack of adherence to amiodarone monitoring and
urges those in this specialty area to evaluate current monitoring protocols for adherence rates.
Future clinics led by APNs might also incorporate other antiarrhythmic medications requiring
diagnostic monitoring as well as other medications used in the treatment of chronic diseases.
Not only can this provide another area of expertise for APNs to fulfill, but also improvement of
patient outcomes through early awareness of drug adverse effects.
Conclusion
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The evaluation of this EBP project suggests that implementation of an APN-led
amiodarone clinic increases adherence to amiodarone monitoring guidelines. A review of the
literature identified that other amiodarone clinics also improved adherence to amiodarone
monitoring guidelines, but none were found that were APN-managed. Some of the research
identified patients who had already suffered amiodarone adverse effects that had gone
unnoticed by current healthcare providers, giving further indication for a dedicated amiodarone
clinic. Through patient interactions, patient education, and assessment of barriers and stressors
to adherence to diagnostic monitoring, improved awareness and early recognition of
amiodarone adverse effects may be achieved through mutual goal attainment. Patient education
skills and the ability to monitor health status in a holistic manner are already ingrained into the
APN role, leading to the opportunity of a new function in healthcare.
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ACRONYM LIST
ALT: alanine transaminase
APN: advanced practice nurse
AST: aspartate transaminase
CXR: chest x-ray
DLCO: diffusing capacity of the lungs for carbon monoxide
EBP: evidence-based practice
FT4: free thyroxine
HRS: Heart Rhythm Society
INR: international normalized ratio
LFT: liver function test
TFT: thyroid function test
TSH: thyroid stimulating hormone
PFT: pulmonary function testing
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Appendix A
AMIODARONE PATIENT EDUCATION
Guidelines for Therapy
Your doctor has prescribed amiodarone for you. This medicine is used to treat irregular
heart rhythms. While you are taking this medication, you will need to complete testing before
you start the medication and every six months while taking the medication. It is preferred that
you take this medication with food at the same time every day. You should avoid drinking
grapefruit juice or eating grapefruits. This may decrease the effects of the medication. Please
report all medications you are taking to your cardiologist as well as any new medications you
may start. Some medications may react with amiodarone. They may increase or decrease the
effects.
Here are the lists of tests that must be completed at the start of your treatment and at certain
intervals while on amiodarone. Any of these tests may be completed at any time in the future if
side effects are suspected.
At Baseline

Every 6 Months

Yearly

Liver function test
Thyroid function test
Pulmonary function test
Chest x-ray
Eye exam
EKG

Liver function test
Thyroid function test

Chest x-ray
Eye exam
EKG

Side Effects
Side effects are more likely to occur at higher doses during the loading period. Most side
effects lessen or go away with a decrease in dose. Amiodarone stays in your body for a long
period of time. If the medication is stopped, the effects may still remain in your body for several
weeks or months. Please call your cardiology provider if you experience side effects, which may
include:
Shortness of breath/cough
Nausea and vomiting
Skin discoloration

Sensitivity to the sun
Tiredness/fatigue
Blurry or double vision

Loss of appetite
Constipation
Muscle weakness/tremors
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Lung problems
In a small number of patients taking amiodarone over a long period of time, lung damage
can occur. This damage can be lessened or reversed completely if amiodarone is stopped early.
If you develop shortness of breath or a cough, please tell your cardiology provider immediately.
Skin reactions
Your skin may develop a redder look. This may increase when exposed to sunlight. A
bluish-gray discoloration may also be seen. These reactions are normal side effects.
Sunscreen, hats, and long-sleeves/pants are recommended to help decrease these effects.
Eye problems
Amiodarone can sometimes deposit small particles in the eye. Sometimes blurry or
double vision can occur. These deposits can be seen on a thorough eye exam by an
ophthalmologist (eye doctor). If eye deposits are seen on exam and are causing vision loss, the
amiodarone dose may have to be decreased or stopped completely.
Sleep Disturbances
While taking amiodarone, you may experience changes in sleep patterns. Insomnia is
common, especially during the loading period. This will lessen as the dose is reduced. If
insomnia is a problem, please discuss this with your cardiology provider for treatment options.

As with any medication, your doctor will determine if the benefits of amiodarone
outweigh the risks or complications due to side effects. If you experience side effects,
please contact your cardiology provider. A dose adjustment or further testing may be
needed.
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Appendix B
Amiodarone Clinic Patient Evaluation Protocol
I.

II.

At the initial visit:
A. Basic history and physical
1. Vital signs: BP, HR
2. Lung exam
3. Heart exam
4. Review of current medication list to check for potential drug
interactions with amiodarone
B. Baseline tests if not obtained at cardiology consultation
1. CXR
2. EKG
3. Pulmonary function test
4. Ophthalmology exam
5. CMP, Magnesium, TFT (and PT/INR and/or digoxin level if
appropriate)
C. Patient education on amiodarone use, side effects, interventions to decrease
side effects
At the one month visit:
A. Basic history and physical to elicit for adverse effects
1. Fatigue
2. Cough/shortness of breath
3. Palpitations
4. Syncope
5. Blurry/double vision or loss of vision
6. Skin changes
7. Weight loss/nausea/vomiting
8. Muscle weakness/tremors
9. Sleep disturbances
10. Changes in medications
B. Discuss baseline testing
C. Order further testing based on baseline testing results or patient complaints of
side effects
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Appendix C
Code # ________
Amiodarone Clinic Data Collection Tool
Patient Age: __________ Patient Height: __________ Patient Weight: __________
New to Amiodarone? __________ If no, length of amiodarone use: __________
Date of Initiation: __________ Warfarin? __________ Digoxin? __________
Past Medical History:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Current Medications:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________

Baseline
H&P
EKG
TFT
LFT
CXR
PFT
Eye
Exam
Digoxin
Level
INR

Week
1

Week
2

Week
3

Week
4

Week
5

Week
6

3
Month

6
Month

1
Year
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*shaded boxes indicate when diagnostic study is needed (3 month testing optional)
*place date of exam in box
Recheck as Needed for Symptomatic Adverse Drug Reactions
EKG
TFT
LFT
CXR
PFT
Eye
Exam
Digoxin
Level
INR
*place date of exam in box

75

EFFECTS OF AN APN-LED AMIODARONE CLINIC

76

Appendix D
Amiodarone Clinic Code Key
Code Number

Patient Name

Date of Birth

Medical Record #

